



Curriculum Vitae

David F. Jarrard, MD

University of Wisconsin
School of Medicine and Public Health
Department of Urology
1685 Highland Avenue
Madison, Wisconsin 53705-2281

608.262.0759
608.262.6453 Fax
jarrard@urology.wisc.edu

Education

- 1980-1984 Bachelor of Arts-Chemistry, Art History Minor University of Virginia, Charlottesville, VA
- 1983 Study Program in Florence Italy, Art History (University of Michigan)
- 1985-1989 Doctor of Medicine, University of Virginia School of Medicine, Charlottesville, VA
- 1989-1990 Junior Resident in General Surgery, University of Chicago Hospitals, Chicago, IL
- 1990-1994 Chief Resident and Resident in Urology, University of Chicago Hospitals, Chicago, IL
- 1994-1996 Urologic Oncology Fellow, American Foundation for Urologic Disease (AFUD), Johns Hopkins Hospital, Baltimore, MD

Certification and Licensure

- 1998- American Board of Urology, Certification in Urology
- 1998- American Board of Urology, Subspecialty Certification in Urologic Oncology
- 1996- Medical License, State of Wisconsin
- 1989- Medical License, State of Illinois

Present Appointments/Positions

- 2021- Deputy Director**, University of Wisconsin Carbone Cancer Center
- 2008 Vice Chair of Urology**, Department of Urology, University of Wisconsin, Madison, WI
- 2011 Member**, Wisconsin Institutes for Discovery, Epigenetics Program
- 2008 Professor (tenured)** Department of Urology, University of Wisconsin School of Medicine, Madison, WI
- 2008 Professor**, Molecular and Environmental Toxicology, University of Wisconsin Graduate School, Madison, WI
-

- 2005 **John P. Livesey Chair in Urologic Oncology**, Division of Urology, University of Wisconsin, Madison, WI
- 1999 **Member**, University of Wisconsin Institute on Aging, University of Wisconsin Graduate School, Madison, WI
- 1998 **Member**, Molecular and Environmental Toxicology Program, University of Wisconsin Graduate School, Madison, WI
- 1996 **Member**, University of Wisconsin Carbone Comprehensive Cancer Center, University of Wisconsin, Madison, WI

Past Appointments/ Positions

- 2016-2021 **Associate Director, Translational Research**. University of Wisconsin Carbone Cancer Center
- 2006-2021 **Head**, Division of Genitourinary Oncology, Dept. of Urology and **Co-leader** GU Multidisciplinary Oncology group
- 2013-2020 **Director**, UW Society of Urologic Oncology Fellowship
- 2014-2016 **Co-Director**, Aging and Chemoprevention Program, University of Wisconsin Carbone Cancer Center
- 2002-2008 **Associate Professor (tenured)**, Department of Surgery, Division of Urology, University of Wisconsin School of Medicine, Madison, WI
- 2002-2008 **Associate Professor (tenured)**, Molecular and Environmental Toxicology, University of Wisconsin Graduate School, Madison, WI
- 1996-2002 **Assistant Professor**, Department of Surgery, University of Wisconsin School of Medicine, Molecular and Environmental Toxicology Section, University of Wisconsin Graduate School, Madison, WI
- 1994-1996 **Instructor in Urology**, Department of Urology, Johns Hopkins Hospital, Baltimore, MD

Honors and Awards

- 2022 Dean's Award for Excellence in Medical Student Research Mentorship UWSMPH
- 2021 Elected to the American Association of Genitourinary Surgeons (AAGUS)
- 2017 AUA Lectureship, Fall Meeting for Society for Basic Urologic Research. Tampa, FL
- 2017 WARF Innovation Award, Finalist and Winner: Independent panel annually selects best patent from 400 disclosures filed with the Wisconsin Alumni Research Fund.
- 2015 Distinguished Service Award, Society for Urologic Oncology
Alpha Omega Alpha (AOA) Honor Medical Society
- 2014 Distinguished Service Award, Society for Basic Urologic Research (SBUR)
- 2012 Best Poster Award, American Urological Association National Meeting: Advanced Prostate Cancer; Babian *et al*, "*Analysis of urological procedures in men who died from prostate cancer using a population-based approach*"
- 2011-Present Castle Connolly Top Doctors

2008	Best Poster Award, American Urological Association National Meeting: Basic Science; Ewald et al., " <i>The induction of senescence as therapy for prostate cancer</i> "
2006	Harold Rausch Translational Research Scholar, University of Wisconsin Medical Alumni Association Annual Award
2005–Present	John Livesey Chair in Urologic Oncology, Endowed Chair
2005-Present	Selected "Best Doctors in America™", Best Doctors Inc. Aiken, South Carolina.
2004-Present	Selected "Best Physicians -Urology", <u>Madison Magazine</u> .
2001	Society of Basic Urologic Research Young Investigator Award. Alpha Omega Alpha (AOA) National Medical Honor Society
1999	Pfizer Scholars in Urology Award.
1999	American Urological Association National meeting, Third Prize -Basic Science Research Annual Essay Contest, " <i>Alterations in the P16/retinoblastoma pathway is required for overcoming senescence in prostate epithelial cells</i> '.
1995	Society for Basic Urologic Research, First Prize -Research Essay Contest
1994	American Foundation for Urologic Disease (AFUD) Research Scholar (George Sheehan Foundation)
1994	Chicago Surgical Society, Basic Science Award
1992	Chicago Urological Society, Charles B. Huggins Resident Essay Contest, Basic Science Award
1991	Chicago Urological Society, Charles B. Huggins Resident Essay Contest, Clinical Science Award
1980-1984	Dean's List, University of Virginia
1980	Stuart P Brubaker Award, Lexington High School (Graduating senior athletic Letterman with highest GPA), Lexington, VA

Professional Societies and Service

- North Central Section, American Urological Association, President (2018-2019); Member Executive Board (2017-2020). Member (1996-present), Finance Committee (2010-12).
- Society of Academic Urologists (SAU), President (2020-2021); Treasurer and Executive Board (2017-2019); Chair, Research Committee (2016-2018)
- Society for Urologic Oncology. Executive Board and Elected Member at Large (2014-2017), Rapid Response Committee, Chair (2018-2024), Awards Committee (2020-2021), Fellowship Committee (2016-2019), Member (2004-present), Chair AUA-SUO Spring Meeting (2014 and 2015).
- American Urological Association. AUA Research Council Education, Conferences and Communications Chair (2021-2023) and member (2014-present); AUA Clinical Research Education Steering Committee (2020-2022), Abstract Reviewer (2007-present), Research Council (2010-12), Education Council (2010-2012), Member (1990-present)
- American Urological Association Course Director. Advanced Prostate Cancer Live Forum for Residents and Fellows (2017-2018). AUA series lectures and roundtable discussions held on the urologic management of advanced prostate cancer
- American Urological Association Guidelines on Castration Resistant Prostate Cancer. Expert Panel that generates guidelines for management of urologic diseases (2018-present).
- National Comprehensive Cancer Network (NCCN) Prostate Cancer Early Detection Panel Member (2016-present)

- Society for Basic Urological Research. President (2010-11), Vice President (2009-10), Executive Committee Member at Large (2006-08). Member (1996-present), Co-Chair SBUR Annual Spring Meeting (2010), SBUR Fall Meeting Organizing Committee (2009).
- American Journal of Clinical and Experimental Urology, Editorial Board (2013-present).
- IMPACT Planning Meeting, Executive Board Member (2007).
- NIDDK Planning Meeting on the Future of Urologic Research, Member. (2007).
- Department of Defense Prostate Cancer Research Program. Reviewer (1999-2006), Study Section Chair (2005-2007), Integration Panel (2009-2013), Member Executive Board (2010-13). Integration Panel *Ad hoc* reviewer (2015-2019)
- Wisconsin Urologic Society. President (2005-06), Executive Board (2004-2007), Member (1997-present), Chair Spring meeting (2006).
- ALLIANCE (Eastern Cooperative) Oncology Group, Member (1996-present), Head GU subcommittee (2005-08).
- American Association of Cancer Research. Member (1996-present).

Academic/Executive Education

2016	Kellogg School of Business Northwestern University - Society for University Surgeons, Executive Education Leadership Agility Program (28 hours)
2015	American Association for Physician Leadership, Physician in management seminar series (35 hours)
2012-2013	Professional Development Leadership Program, UW-Madison Business School, (18 month program, 150 hours teaching finance, negotiation, management and other healthcare leadership skills)

University and Hospital Service (Administrative & Committees)

Present

2020-	Robotics Program, UW Health, co-Chair.
2018-	UW Medical Foundation Finance Committee.
2017-	Chair, Drug and Biomarker Discovery Consultation Panel, UW Carbone Cancer Center. Panel of biotech leaders who review and prioritize translational research
2015-	UW Health Oncology Steering Committee, Member (Regional cancer services and long-range planning group)
2014-	UW Carbone Comprehensive Cancer Center, Deputy Director (2021-), Associate Director for Translational Research (2016-2021), Executive Committee (2016-present), Senior Leader Committee (2016-present), Co-leader Aging and Cancer Prevention Program (2014-16).
2011-	Operating Room Committee (Surgeon Advisory Committee), Member.
2005-	Department of Urology, Vice-Chair; Executive Committee. Promotions.
2001-	Tissue Storage Repository Advisory Committee, UW Carbone Comprehensive Cancer Center, Member.

Past

2017-2022	Academic Senior Leadership Council (12-member advisory body for the Dean of the School of Medicine tasked with advancing academic missions, direct resource allocation and improving operational efficiency)
2018-2020	Academic Department Budget Process (ADBP) Workgroup. Create metrics to determine the budget a Clinical Department needs for research and education
2017-2020	Ambulatory Access Workgroup, Member
2013-2022	Dept. Urology Quality Improvement Committee, Member

2016- 2021 UWH Inpatient Operations Council, Member.
 2015- 2021 Inpatient Dyad co-leader, Urology and Gynecology
 2010-2018 Compensation Committee Department Urology, Chair
 2017, 2020 Chair, Urology Oncology Faculty Search Committee
 2009-2020 Hospital Robotics Committee UWHC.
 2014-2017 UW Health Clinical Affairs Committee, Member.
 2014-2015 Pediatric Urology Search Committee, Member.
 2013-2015 School Medicine and Public Health Tenure Track Promotions Committee, Member.
 2013 Urology VA Search Committee, Chair.
 2012-2016 Hospital Quality Improvement Council, Member.
 2011-16 UW Carbone Comprehensive Cancer Center, Outreach Steering Committee, Member.
 2010-14 Faculty Senate Representative, Department of Surgery/Urology, University of Wisconsin, Primary/Alternate.
 2010 Pathology Chair Search Committee 2010, Member.
 2009-2012 Academic Planning Council, Advisory Board to Dean.
 2009 Urologic Research Faculty Search Committee, Head.
 2009 Aging and Cancer (Geriatrics) Faculty Search Committee, Member.
 2008-2017 UW Carbone Comprehensive Cancer Center, Co-leader Genitourinary Cancer Disease Oriented Working Group
 2008-2016 University of Wisconsin Health Ambulatory Operations Committee, Member.
 2008-2015 PHLAG (Physician Healthlink Advisory Group), Member.
 2008-2010 T32 Oncology Training Grant advisory committee, Member.
 2008-2010 School of Medicine and Public Health Promotions Committee, Member.
 2008-2010 Faculty Senate Representative, Department of Surgery/Urology, University of Wisconsin.
 2007-2009 Environmental Toxicology Training Grant Advisory Board, Member.
 2007 Drug Action Faculty Search Committee, Dept. of Pharmacology, Member.
 2006-15 UWCCC K12 Training Grant Advisory Board, Member.
 2005-2006 NIH/NIEHS Environmental Toxicology Pre-doctoral and Postdoctoral Training. Grant Committee, Member.
 2004-2006 Faculty Senate Representative, Department of Surgery/Urology, University of Wisconsin.
 2003-2007 Director for Urology Medical Student Education, UW Medical School.
 2003-2004 Review Committee for the Genomics and Proteomic Shared Service, UW Comprehensive Cancer Center, Member.
 1997-2006 Surgical associates Grant Review Committee, Member.
 1996-2001 Clinical Research Committee- UWCCC, Member.
 1996 Ad Hoc Committee on Service, Research and Teaching, Department of Surgery, Member.

Journal Reviewer

Editorial Board, *American Journal of Clinical and Experimental Urology* (Journal for the Society for Basic Urologic Research)

Reviewer, *Cancer*

Reviewer, *Journal of the National Cancer Institute*

Reviewer, *Oncogene*

Reviewer, *Annals of Surgery*

Reviewer, *Prostate*

Reviewer, *Clinical Cancer Research*

Reviewer, *Cancer Research*
 Reviewer, *Urology*
 Reviewer, *Oncology*
 Reviewer, *Journal of Urology*
 Reviewer, *Journal Clinical Oncology*

Extramural Research Support

Major Past Awards

- 1994-1996 "Characterization of DNA hypermethylation and genetic alterations in the development of benign prostatic hyperplasia," AFUD (**Jarrard**, PI) \$40,000.
- 1997-1999 Howard Hughes Medical Institute "Epigenetic mechanisms of prostate cancer progression" (**Jarrard**, PI) \$47,019.
- 1998-1999 National Institutes of Health "New Model of Human Bladder Cancer Pathogenesis" Co-Investigator (PI Catherine Reznikoff) \$1,123,347.
- 1998-2003 National Institutes of Health K08 Clinical Scientist Development Award (CA76184-01) "Genetic events in human prostate cell transformation" (**Jarrard**, PI) \$449,999.
- 1999-2003 National Institutes of Health "A Randomized Controlled Phase 2 Clinical Trial of Intermediate Endpoint Biomarkers by Chemopreventive Agents in Patients with Clinically Localized Prostate Cancer and High Grade PIN" Co-Investigator (PI George Wilding) \$210,000.
- 2001-2003 American Federation for Aging Research "Genomic imprinting alterations in Senescence" (**Jarrard**, PI) \$50,000.
- 2001-2004 Department of Defense Prostate Cancer Research Program "Relaxation of Insulin-Like Growth Factor II Imprinting in Prostate Cancer" (**Jarrard**, PI) \$320,000
- 2001-2004 Department of Defense Prostate Cancer Research Program "Understanding Molecular Mechanisms of Androgen-Induced Oxidative Stress for Chemoprevention of Prostate Cancer" Co-Investigator (PI George Wilding) \$356,000
- 2002-2003 Department of Defense Post-Doctoral Fellowship "Role of Cdc37 in Overcoming p16 Mediated Growth Arrest in Prostate Cancer" Mentor (PI Steven Schwarze) \$140,000.
- 2002-2003 CaPCURE "The Induction of Cellular Senescence as a Novel Anticancer Therapy" (**Jarrard**, PI) \$100,000.
- 2002-2007 NIH R01 (1R01CA97131) "Modulation of IGF-II imprinting in the aging prostate" (active, effort 35%) (**Jarrard**, PI) \$1,584,550.
- 2003-2004 CaPCURE "Cellular Senescence as a Novel Anticancer Therapy" Co-Investigator (DF Jarrard and G Wilding) \$150,000.
- 2003-2008 NIH, George M. O'Brien Urology Research Center (1P50 DK065303)(active, effort 15%) "Mechanisms for Acquired Changes in Prostate Growth Regulation" (**Jarrard**, PI) Project 3 \$688,722 (\$125,000 for the project.)
- 2003-2008 NIH/NCI, Integrating Aging and Cancer Research in NCI Designated Cancer Centers (1 P20 CA103697-01 active, effort 5%) **Co-investigator**, (PI: R. Weindruch) Co-leader Biology of Aging, \$402,749.
- 2004-2005 Prostate Cancer Foundation (CapCURE) "The Induction of Senescence as Novel Anticancer Therapy" (**Jarrard**, PI) \$100,000.

2005-2009	Department of Defense Prostate Cancer Research Program “Biological Impact of Senescence Induction in Prostate Cancer Therapy” PC050690 (Jarrard , PI), \$420,000.
2005-2009	NIH (R01 CA114060-01A1) “SELECT Pre-Clinical Trial of Prostate Cancer” Co-investigator (Nihal Amhad, PI) \$530, 000.
2006-2007	Wisconsin Alumni Research Fund “Screening for senescence using whole cell high-throughput robotic assays” (Jarrard , PI) \$25,000.
2006-2008	NIH "UWCCC Participating Center Application for Prostate Cancer Research Program Clinical Consortium Award" Role: Co-Investigator (Wilding, PI) \$500,000.
2006-2010	NIH (R01) “Impact of CHESS and prostate cancer mentor on treatment” Co-investigator (Robert Hawkins PI) \$520,000.
2006-2010	NIH R01 “Folic Acid Enhances Repair Mechanism in the Adult CNS” Co-Investigator (Iskandar, PI) \$229,639.
2006-2016	DOD/Army W81XWH-09-1-0142 (PI: Wilding) UWCCC Participating Center: Prostate Cancer Research Program Clinical Consortium Award, Role: Co-Investigator. Improve clinical trial accrual rates, efficiency and data standardization, and accelerate the drug development process within the PCRP Clinical Consortium.
2008-2009	American Urological Association Research Grant “Modulation of IGF-II imprinting in the aging prostate” (Jarrard , PI) \$25,000. A bridging grant for my RO1.
2008-2009	NIH R56 (1R01CA97131) “Modulation of IGF-II imprinting in the aging prostate” (active, effort 20%) (Jarrard , PI) \$249,689.
2009-2014	NIH R01 (2R01CA97131) “Modulation of IGF-II imprinting in the aging prostate” (active, effort 20%) (Jarrard , PI) Dates of Award: 8/1/09-7/30/14, \$1,836,850.
2010	American Urological Association Herbert Brendler Summer Research Grant “Methylation Field Effect in Prostate Cancer” Mentor (Student: Andrew Livermore, BS) \$3000.
2010-2012	Department of Defense Post-Doctoral Fellowship “Role of CTCF in Prostate Cancer” Mentor (P.I. Dr. Sachin Bhusari/Jin Lee) \$140,000.
2012-2014	UWCCC Investigator Initiated Trials “Discovering Chemical Probes for Therapy-Induced Senescence (TIS)” PI Jarrard/Hoffman Dates of Award: 10/12-10/13, \$50,000.
2012-2017	NIH N01 (CN35156) (PI H. Bailey) Role: Co-Principal Investigator Phase I and Phase II Clinical Trials of Cancer Chemopreventive Agents. \$900,000 annual to program.
2014-2016	UW Igniter Award. Development of the EpiView Clinical Assay (Role: Principal Investigator) \$150,000. Funding to bring a molecular assay to clinical development.
2013-2018	NIH/NCI - 1K08CA178168-01 “Role of NF-κB/ HIF2α axis in renal cell carcinoma” Role: Mentor (Abel, PI) \$175,163 Mentored clinical scientist development award
2015-2018	DOD PCRP Idea Development Award (PC140574) “Targeting Dysregulated Epigenetic Enzymes for Prostate Cancer Treatment”. Role: Principal Investigator . New histone reader technology to identify and target altered histone modifying enzymes in castrate-resistant prostate cancer. \$125,000 annual (573,000 total) 2015-2019
2015-2018	NIH (Smith-PI) Role: Co-Principal Investigator 1R01CA193481-01 “Sequence-specific Capture for Discovering Protein-lncRNA Interactions in Prostate Cancer” Utilizing new technology to map splice variants and their protein products in aggressive prostate cancer. \$210,000 annual.

- 2014-2019 NIDDK - R01DK099328 (Chad Vezina, PI) **Role: Co-investigator.** NIH/NIDDK Co-PI "Role of DNA methylation in prostate glandular development and urinary function" \$1,087,000 The goal is to determine how DNA methylation controls prostate glandular development and how its actions during development and in adulthood impact urinary function.
- 2016-2018 DOD/PCCTC Award (PI: Liu/McNeel) UWCCC Participating Center: Prostate Cancer Research Program Clinical Consortium Award, **Role: Co-Investigator.** The goal of this project is to contribute to the improvement of clinical trial accrual rates, and accelerate the drug development process within the PCRCP Clinical Consortium.
- 2016-2019 DOD PCRMP Idea Development Award-Partnering PI – Project Award (PC150221) “Synthetic lethal metabolic targeting of senescent cells after androgen deprivation therapy” **Role: Principal Investigator.** Metabolic approach using metformin to improve androgen deprivation treatment for prostate cancer. (\$1.2M total; \$750,000 to Jarrard lab)
- 2016-2019 DOD PCRMP Impact Award - Partnering PI Option (PC150332) Fusion genes predict prostate cancer recurrence. Luo PI. **Role: Co-Principal Investigator.** Setting up and testing a series of novel fusion genes for their prognostic outcomes. (Total \$3.1M; \$826,200 to Jarrard lab)
- 2016-2019 DOD PCRMP Impact Award – Partnering PI Option (PC150536) Functional and Molecular Diversity in the Tumor Microenvironment Underlies Therapeutic Response and Resistance. Lang PI. **Role: Co-Principal Investigator.** Multi-investigator study evaluating heterogeneity in the prostate cancer tumor microenvironment (Total \$3 M; \$848,420 to Jarrard lab)
- 2018-2019 American Urological Association/Urology Care Foundation Research Scholar Award. Khemees PI. **Role: Mentor.** Improving Androgen Deprivation therapy by Synthetic Lethal Metabolic Targeting.
- 2019-2022 Department of Defense PCRMP Post-Doctoral Fellowship “CHD1-Deficiency Engenders a Distinct Epigenetic Profile in Castration-Resistant Prostate Cancer” **Role: Mentor** (P.I. Joe Gawdzik, PhD) \$150,000.
- 2021-2022 American Urological Association/Urology Care Foundation Research Scholar Award. Esdaille PI. **Role: Mentor.** RACE Study: Understanding the impact of racial differences in pharmacologic modulation of the Androgen deprivation therapy (ADT) response on a systemic level and within prostate Cancer microEnvironments. (\$40,000)
- 2021-2023 Bristol-Myers Squibb training Award (MSN246974). Esdaille PI. **Role Mentor.** “Phase I/II Trial of Androgen Deprivation, with or without pTVG-AR, and with or without Nivolumab, in Patients with Newly diagnosed, High-Risk Prostate Cancer.” (\$240,000)
- 2018-2023 NIH UW Comprehensive Cancer Support (P30CA014520-44). **Role Co-I** Grant for Matrix Cancer Center (\$4.6M annual)

Grant Support Active

- 2019-2024 **NIH (Smith/Jarrard-PI) Role: Co-PI 2R01CA193481-04** “Sequence-specific Hybridization Capture for Discovering Proteoform-lncRNA Interactions in Prostate Cancer” Utilizing new technology to map splice variants and their protein products in aggressive prostate cancer. (Total 2.9M; 1M to Jarrard lab)
- 2017-2025 DOD (W81XWH-22-2-0014). **Role Co-I.** Title: Prostate Cancer Clinical Trials Consortium: University of Wisconsin Carbone Cancer Center. This study will support novel clinical trials endorsed by the PCCTC. (\$1.2M annual)

- 2021-2025 DOD (W81XWH2110270) **Role Co-I.** Title: Phase I/II Trial of Androgen Deprivation, with or without pTVG-AR, and with or without Nivolumab, in Patients with Newly Diagnosed, High-Risk Prostate Cancer. The current protocol will examine the use of a plasmid DNA vaccine encoding Androgen Receptor (AR), alone or with nivolumab, to induce and/or augment therapeutic T-cells following androgen deprivation in participants with newly diagnosed prostate cancer scheduled to undergo prostatectomy. (\$1.2M annual)
- 2023-2028 UWCCC Comprehensive Cancer Support (2P30CA014520-49). **Role Co-I** Grant for Matrix Cancer Center (\$4.6M annual).
- 2023-2026 **DODPCRP (HT9425-23-1-0127) Award PI Jarrard**, (co PI Denu, Lewis). Targeting dysregulated histone-modifying enzymes driving prostate cancer cell survival after androgen deprivation therapy. Aims: To identify functional dependencies on specific histone modifying enzymes (HMEs) in hormone sensitive PC survival after ADT exposure; To Map the expression of candidate histone modifying enzymes in vitro and in human samples after ADT and during the transition to CRPC to identify upregulated, differentially expressed enzymes and determine their functional importance; Optimize synthetic lethal approaches combining ADT with histone modifying enzymes identified as functionally important for survival after ADT. (\$1.4M total)
- 2023-2028 **NCI (P50CA269011) Award PI (Jarrard (comm.)/McNeel) University of Wisconsin Prostate Cancer SPORE.** The specific objectives and goals of the UW Prostate Cancer SPORE include: The broad objectives of this SPORE are to: 1) Increase multidisciplinary translational research and develop the next generation of Prostate Cancer (PC) researchers, 2) Develop common resources to promote advances, 3) Translate promising new approaches into patients and 4) Improve overall survival and quality of life for patients with PC. (\$11.8M)

Clinical Trials

Active

1. NCI Division of Cancer Prevention. **Site PI.** NWU22-12-01: A phase 2 placebo-controlled trial of Urolithin A supplementation in men with prostate cancer undergoing radical prostatectomy. (active 12/2023)
2. DOD (W81XWH2110270) **Role Co-I.** Title: Phase I/II Trial of Androgen Deprivation, with or without pTVG-AR, and with or without Nivolumab, in Patients with Newly Diagnosed, High-Risk Prostate Cancer.
3. Bluemke Foundation (UW 16062) **Co-PI** (Cho/Jarrard) PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Study in Prostate Cancer Active Surveillance (active \$1M total)

Closed

1. Sponsor: Genetics Institute. Investigators: K. Conlin
Trial: Dose-Ranging Study of Intravesical Administration of Recombinant Human Interleukin-12 In Patients With Recurrent Superficial Transitional Cell Carcinoma Of The Bladder.
2. Sponsor: ILEX and NCI (N01 CN2543401) Investigators: M. Sarosdy, E. Messing
Trial: Phase III Randomized, Double-Blind Study of DFMO vs. Placebo in Low Grade Superficial Bladder Cancer
3. Sponsor: NCI Investigators: C. Coltman

4. Sponsor: Sanofi-Aventis Investigators: Kibel/Eisenberger
Trial: C005806: Randomized trial comparing Eligard in combination with docetaxol for patients at high risk of relapse after radical prostatectomy (10/07)
5. Sponsor: NCI Investigators: Hansen and D. Jarrard
(ECOG) Trial: Selenium as chemoprevention for men with high-grade prostatic intraepithelial
6. Sponsor: US HIFU Trial: High-Intensity Focused Ultrasound Treatment for Radio resistant Prostate Cancer (2013)
7. Sponsor: Astellas Trial: 905-UC-050 A Randomized, Double-Blind, Parallel, Placebo-Controlled, Phase 4, Multi-center Study to Assess Efficacy and Safety of VESIcare® (Solifenacin Succinate) to Improve Urinary Continence of Subjects after Robotic Assisted Radical Prostatectomy
8. Sponsor: National Cancer Institute/ Cancer Prevention Investigator: Jarrard
Trial: Phase IIa, randomized placebo-controlled trial of single high dose cholecalciferol and daily genistein (G-2535) versus placebo in men with early stage prostate cancer undergoing prostatectomy. (Role site PI)
9. Sponsor: NCI Division of Cancer Prevention Site Investigator: Jarrard
Trial: Phase II Assessment of the Diagnostic Accuracy of 99mTc-MIP-1404 Imaging in Men with High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (EPLND) Compared to Histopathology. (Role Site PI)
10. Sponsor: UW D2P Principle Investigator: Jarrard
Multicenter Trial of BiopsyAssure in Patients with Elevated PSA and Negative Biopsy. (Completed, multicenter trial)
11. Sponsor: Eastern Cooperative Oncology Group/ACRIN. **co-PI national (Sweeney/Jarrard)**. Trial: **CHAARTED**: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer
12. Sponsor: NCI/Division of Cancer Prevention. **Protocol PI Jarrard**
Trial: 2013-0222, CO11378: A Phase IIA Exploratory, Randomized, Placebo-controlled Trial of Pomegranate Fruit Extract/POMx™ in Subjects with Clinically Localized Prostate Cancer Undergoing Active Surveillance. (multisite trial)
13. Sponsor: Progenics
Site Investigator: Jarrard
Trial: PROTOCOL MIP-1404-3301: A Phase 3 Study to Evaluate the Safety and Efficacy of 99mTc-MIP-1404 SPECT/CT Imaging to Detect Clinically Significant Prostate Cancer in Men with Biopsy Proven Low-Grade Prostate Cancer who are Candidates for Active Surveillance (proSPECT-AS).

Patents

- 2006 Alpha Methylacyl a Coenzyme Racemase Detection in Semen Ejaculate: A noninvasive test for screening for prostate cancer (US 15/383,437; co-inventor.)
- 2015 Unbiased DNA Methylation Markers Define an Extensive Field Defect in Histologically Normal Prostate Tissues Associated with Prostate Cancer: New Biomarkers for Men with Prostate Cancer (US 10,131,953 B2; Inventor)
- 2017 Epithelial Quantitation of Histologically Normal Prostate Tissue Predicts the Presence of Cancer in Tissue Biopsies (pending; US 62/421,554; Inventor)
- 2020 IMAGE ANALYSIS OF EPITHELIAL COMPONENT OF HISTOLOGICALLY NORMAL PROSTATE BIOPSIES PREDICTS THE PRESENCE OF CANCER (US 2020/0202525 A1; Inventor)

Grant Study Sections

- 1999 Molecular Genetics Study Section, Reviewer, Department of Defense Prostate Cancer Research Program
- 2001-2003 Cellular Biology 3, Reviewer, Department of Defense Prostate Cancer Research Program
- 2004 Pathobiology 2, Reviewer, Department of Defense Prostate Cancer Research Program
- 2005, 2006 Study Section Chair, Cellular Biology 2, Department of Defense Prostate Cancer Research Program
- 2005 AUA Foundation/NIDDK Surgeon-Scientist Awards; Panel Member
- 2008 National Institutes of Health Specialized Program of Research Excellence, (SPORE) study section, *ad hoc* reviewer
- 2008, 2013 AUA Foundation Research Scholar Awards, Panel Member
- 2008 National Cancer Institute Program Project Grant, *ad hoc* Reviewer.
- 2010-2012 Department of Defense Prostate Cancer Research Program Integration Panel, Member
- 2011-2012 Department of Defense Prostate Cancer Research Program Executive Board
- 2012, 2013 Irish Cancer Society, Reviewer
- 2013 NIH/NIDDK George O'Brien Center, Reviewer
- 2013-present AUA Foundation: Research Scholars Program, Rising Stars in Urology, AUA Physician Scientist Residency Training Award, Reviewer
- 2014 Stichting tegen Kanker / Fondation contre le Cancer, *ad hoc* reviewer
- 2015, 2016 Department of Defense Prostate Cancer Research Program Integration Panel, *Ad Hoc reviewer*
- 2012-present National Institutes of Health Specialized Program of Research Excellence, (SPORE) study sections, Co-Chair (2017)
- 2018 NIH/NCI Lasker Clinical Research Scholars Program study section, Chair
- 2019-present NIH/NCI Cancer Center Support Grant (CCSG) On-site cancer center reviews of NCI supported cancer centers.

Structured Teaching and Education

- 1996-2000 Urology Residents, Weekly review of *Campbell's Urology* Text.
- 1996-2003 Medical Student Department of Surgery lectures, Monthly formal lecture 3rd year.
- 1997 Medical School, Principles of Neoplasia. "Prostate Cancer Guidelines and Management" Organized panel discussion.
- 1997-2010 UW Medical School, Endocrine/Reproductive Pathophysiology course lectures.

1997-2014	Faculty, University of Wisconsin School of Graduate Studies, Toxicology 625 3 lectures in required Department of Toxicology grad/undergrad course
2000	Instructional Course Faculty, "Understanding Molecular Technology and its application to urology", National meeting American Urologic Association, Atlanta
2000	Outstanding Resident Teacher Award, Urology
2000,2001	Patient Doctor and Society. Course for 2 nd year medical students on physical exam.
2000-2004	Medical School, Principles of Neoplasia. "Prostate Cancer Guidelines and Management" Lectures I organized for 2 nd year medical students
2005	YEPSA: Year End physicians' skills assessment. Oral exam for fourth year medical students on surgical problems.
2003-2006	Director for Medical Student Education, Department of Urology
2010-14	Program Evaluation Committee, University of Wisconsin Urology Residency
2013, 2018	Mentor, Shapiro Medical Student Annual Scholarship
2013, 2018	Mentor, AUA Foundation Brendler Medical Student Research Program
2005-2018	Physician Assistant Training Program, "Prostate Cancer". Lecture for second year physician assistant students
2009-present	Small group learning session "Prostate Cancer." Bimonthly lecture given in the Socratic Method to rotating 3 rd and 4 th year medical students, Dept. Urology
2013-present	Mentor, Shapiro Medical Student Summer Research Program
2013-2020	Director and founder, Society for Urologic Oncology Fellowship
2015-present	Resident Mentorship Program, Dept. Urology
2017-present	American Urological Association Course Director. Castration Resistant Prostate Cancer (CRPC) Live Forum for Residents and Fellows. Lectures and roundtable discussions held at multiple venues on the urologic management of CRPC
2017	Discussant and moderator, 'The Poor Learner – What Departmental and Institutional Tools Exist?' Society for Academic Urology Program Directors and Coordinators Annual Meeting, Miami FL
2016-2021	Executive Board Society for Academic Urology (Society charged with running the Urology match and advancing resident academic affairs)
2018	Instructional Course Faculty, Lectures on advance prostate cancer management American Urological Association Annual Meeting. San Francisco, CA.
2018-present	Co-Director and Speaker. AUA Office of Education. .Series of live webinar and podcasts on new approaches in the management of advanced prostate cancer.
2020	Faculty mentor for Early Career Investigator Workshop AUA Foundation
2021-present	Oral Boards Examiner, American Association of Urology

Training Grants

1. Agency: National Institutes of Health/NIEHS (5-T32-ES007015)
Grant Title: Environmental Toxicology Predoctoral and Postdoctoral Training (Elfarra)
2. Agency: NIH (5-T32-CA009135)
Grant Title: Training in Cancer Biology (Sugden)
3. Agency: National Institutes of Health and National Institute on Aging (5-T32-AG000213)
Grant Title: Biology of Aging and Age-Related Diseases Training (Asthana)
4. Agency: NIH (5-T32-CA090217)
Grant Title: Surgical Oncology Research Training Program (Greenberg)

Trainees

Postdoctoral Mentees and Fellows

1997-1999	Hidefumi Kinoshita, MD, PhD, (Current Position: Professor and Chair Kansai University, Kansai Japan).
2000-2004	Steven Schwarz, PhD, (Molecular and Cellular Biology Training grant T32 CA09681 “Molecular Mechanisms Regulating Cancer Cell Proliferation” and Department of Defense Postdoctoral fellowship “Role of Cdc37 in Overcoming p16 Mediated Growth Arrest in Prostate Cancer.” (Current Position: Associate Professor, Program Director Medical Lab Science, University of Kentucky)
2004-2007	Joe Dobosy, PhD, (Funding: National Institute for Aging T32) Project “Modulation of imprinting with aging in the prostate.” (Current Position: Senior Staff Scientist, Integrated DNA Technologies)
2004-2011	Jonathan Ewald, PhD, (Molecular and Cellular Biology Grant T32 CA09681) Project “Mechanisms for inducing senescence in cancer cells” (Current Position: Professor Quinnipiac University Nutter School of Medicine, Springfield MA)
2006-2008	Timo Laurila,,MD “Androgens and Senescence” (Current Position: Consulting Urologist Attendo Finland)
2009-2011	Suchin Bhusari, PhD, (Funding: DOD PCRMP Postdoctoral Fellowship) “Role of CTCF in prostate cancer” 2009-11 (Current Position: The Coca-Cola Company - Global Scientific and Regulatory Affairs).
2012-2013	Matthew Truong, MD “Epigenetic markers for cancer detection”, (Funding Yearlong Shapiro Scholarship UWSOM, Current Position: Asst Professor Cleveland Clinic)
2012–2014	Jin Hee Lee, PhD. (DOD PCRMP Postdoctoral Fellowship) “Role of CTCF and histone modifying enzymes in prostate cancer.” (Current Position: Senior Research Scientist - PPD)
2013-2018	Jason Abel, MD. Asst Professor “Role of NF- κ B/ HIF2 α axis in renal cell carcinoma”, Mentored clinical scientist development award NIH/NCI - 1K08CA178168-01 Current Position: Professor UW
2014-2016	Michael Blute Jr, MD Fellow Project “Induction of Senescence as Therapy”. (Funding Physician-Scientist training grant T32 CA090217, Current Position: Assistant Professor, Creighton Dept Urology)
2015-2016	Pablo Sierra, Urology Fellow “Active Surveillance for Prostate Cancer”. Funding source: Urologic CES School of Medicine (www.urologiaces.com), Medellin, Columbia (current position: Assistant Professor: Universidad del Valle, Cali, Colombia)
2016-2020	Joseph Gawdzik, PhD (Funding Department of Defense PCRMP Post-Doctoral Fellowship) “CHD1-Deficiency Engenders a Distinct Epigenetic Profile in Castration-Resistant Prostate Cancer’ (Current Position: Senior Scientist-Invenra)
2016-2018	Shivashankar Damodaran, MBBS, MCH Society Urologic Oncology Fellow. Project “Epigenetic alterations as markers for prostate cancer” (current position: Urologist Oncologist Lake Huron Medical Center)
2017-2018	Tyler Etheridge MD. Project: ‘Markers of cancer aggressiveness in normal prostate tissue’ (Funding ICTR-Shapiro Yearlong Scholarship, resident Ophthalmology Utah)
2018-2020	Tariq Khemees, MD AUA Foundation Scholar and SUO fellow Project (Statins and ADT as synthetic lethal therapy for prostate cancer) (Funding AUA Foundation) (Current: Urologic Oncology OhioHealth Dublin Methodist Hospital.)
2019-2020	Miko Filon, MD. Project ‘Metabolomic analysis of prostate cancer after androgen deprivation therapy’. (Resident Urology University of Utah)
2020-2022	Ashanda Esdaille. Project:’ RACE Study: Understanding the impact of R acial differences in pharmacologic modulation of the A ndrogen deprivation therapy

response on a systemic level and within prostate **Cancer** micro**E**nvironments'.(Funding: AUA Foundation Scholar; Bristol-Myers Squibb Foundation) (Current Position: Asst Professor, Emory University.
 2022-2024 Marcelo Bigarella. Project 'Histone Modifying Enzymes Predict Cancer Outcomes After ADT'. (current fellow)

Graduate Students

2000 Carol Sandefur, Environmental Toxicology summer student, T32 Toxicology training grant.
 2002-2004 Mara Feld, "Alterations in genomic imprinting with aging", Masters/PhD in Molecular and Environmental Toxicology.
 2003 Maliye Onwueme, Environmental Toxicology summer student, T32 Toxicology training grant.(Pediatric Dentist, Richmond TX)
 2004-2006 Jennifer Lea Roberts, "Alterations in genomic imprinting with aging and carcinogen exposure". Masters in Molecular and Environmental Toxicology.
 2006-2011 Josh Dosetelle, "Senescence in prostate cancer". PhD in Molecular and Environmental Toxicology Program. (Current Position: Lab Director, Dept Oncology UW)
 2012–2016 Nathan Damaschke, "Epigenetic alterations as susceptibility factors for prostate cancer", PhD Cancer Biology Program, funding training program (Postdoctoral fellow Northwestern University, Dr L Yu)
 2020- Tanaya Purohit, "Histone lysine methyltransferase dysfunction in advanced prostate cancer", PhD candidate, Cancer Biology Program

Urology Residents*

1995-1999 Lynn E.Hahnfeld, MD
 1995-2000 Timothy B. Grossman, MD
 1997-2002 D. Brooke Johnson*, MD
 Paul T. Fadden, MD
 Michael Wilkin, MD
 A Johnson MD
 1999-2004 Steven N. Han*, MD
 2007-2012 N Moore* MD
 Sara Best* MD
 2007-2012 AC King* MD
 2011-2016 Jonathan Shiau,* MD
 2013-2019 Jonathan Wang*, MD
 2015-2020 Natasha Posielski*, MD
 2020-2025 Arighno Das*, Ali Ghasemzadeh*

**Projects resulting in published articles.*

Medical Students

Mentored/funded projects resulting in published articles and subsequent career choices:
 Greg Horowitz (Urology, UW),
 Andrew Livermore* (Orthopedic Surgery, UW),
 Josh Modder (Urology, Northwestern),
 Matt Truong* (Assistant Prof. Urology, U Rochester),
 Chad Guenther* (Assistant Prof. Internal Medicine UTSW),
 James Rindt* (Family Medicine, UW),
 Jennifer Wagner* (Internal Medicine, Harvard)

Tyler Etheridge* (Ophthalmology, Utah)
Andrew Truong (Funded through AUA Foundation Brendler Scholarship)
Miko Filon* (Urology Resident, University of Utah)
Nihal Aman*
Jonathan Le*
Arun Augustine*
Diana Garcia*
Emily Schmitt*
**Funded through Shapiro Scholarships*

Thesis Committee Member

Chris Sprague*
Derik Wheeler**
Yafan Lee*
Diantha Kelman*
Brittany Jung*
Weihua Shan*
Bayli Boehm*
Tamara Rodems, Cancer Biology Program
Maisie Steinbrink*
Lily Miller, Biochemistry
KARLA ANAYA ALDRETE
**Environmental Toxicology*
***Human Oncology*

Undergraduates

Biology advisor to over 40 students with pre-medical interests. In addition, 14+ undergraduates have also performed research in my laboratory and several (below) have gone on to successful careers in the sciences and medicine.

Lisa Grabert (MPH Emory, Marquette University Professor Research)
C Sandefur (University of Michigan Graduate Program Biology)
M Kenowski (Graduate school)
Jennifer Kueck (University of Wisconsin-Madison, Oncology Graduate Program PhD)
Nima Almassi, (Medical School MCW, Cleveland Clinic, Urology Resident)
Pushpa Weeratunga, (University of Wisconsin-Madison Law School)
Jennifer Wager, (University of Wisconsin-Madison School of Medicine and Public Health)
Johnathan McCormick: (Medical School University of Miami)
Tian Yao (Graduate school, UCSD)
Cedric Shi (Graduate school, UIC)
Kayla Bahr, Sean Sarosdy

Faculty Mentees

*William Ricke Ph.D., Department of Urology, University of Wisconsin-Madison.
*Sarah McAchran M.D., Department of Urology, University of Wisconsin-Madison.
*E. Jason Abel, M.D., Department of Urology, University of Wisconsin-Madison.
Glen Liu, M. D., Department of Medicine, University of Wisconsin-Madison.
*David Paolone, M.D., Department of Urology, University of Wisconsin-Madison.
Sara Best, M.D., Department of Urology, University of Wisconsin-Madison.

Peter Lewis, Ph.D., Department of Bimolecular Chemistry, Epigenetics, U Wisconsin-Madison
*Kyle A. Richards, M.D., Department of Urology, University of Wisconsin-Madison
Christos Kryiakopoulos, M.D., Department of Medicine, University of Wisconsin-Madison
*Tudor Borza, MD, MPH, Dept of Urology, University of Michigan
David Kozloff, MD, Dept of Medicine, University of Wisconsin
*Committee Chair

Bibliography

Refereed Articles

1. Levine LA, **Jarrard DF**. Treatment of cyclophosphamide-induced hemorrhagic cystitis with intravesical carboprost tromethamine. *J Urol*. 1993 Apr;149(4):719-23. PubMed PMID: 8455230.
2. **Jarrard DF**, Gerber GS, Lyon ES. Management of acute ureteral obstruction in pregnancy utilizing ultrasound-guided placement of indwelling ureteral stents. *Urology* 1993;42(3):263-268. PubMed PMID:8379026
3. **Jarrard DF**, Blitz BF, Smith RC, Patai BL, Rukstalis DB. Effect of epidermal growth factor on prostate cancer cell line PC3 growth and invasion. *Prostate*. 1994;24(1):46-53. PubMed PMID: 8290389.
4. **Jarrard DF**, Hansen NM, Patai B, Rukstalis DB. Urokinase plasminogen activator is necessary but not sufficient for prostate cancer cell invasion. *Invasion Metastasis*. 1995;15(1-2):34-45. PubMed PMID: 7672930.
5. Bales GT, **Jarrard DF**, Gerber GS. Ureteroscopic endopyelotomy in an ectopic kidney. *Urology*. 1995 Jul;46(1):104-6. PubMed PMID: 7604469.
6. **Jarrard DF**, Chodak GW. Prostate cancer staging after radiation utilizing laparoscopic pelvic lymphadenectomy. *Urology*. 1995 Oct;46(4):538-41. PubMed PMID: 7571224.
7. Graff JR, Herman JG, Lapidus RG, Chopra H, Xu R, **Jarrard DF**, Isaacs WB, Pitha PM, Davidson NE, Baylin SB. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. *Cancer Res*. 1995 Nov 15;55(22):5195-9. PubMed PMID: 7585573.
8. **Jarrard DF**, Bussemakers MJ, Bova GS, Isaacs WB. Regional loss of imprinting of the insulin-like growth factor II gene occurs in human prostate tissues. *Clin Cancer Res*. 1995 Dec;1(12):1471-8. PubMed PMID: 9815946.
9. **Jarrard DF**, Bova GS, Isaacs WB. DNA methylation, molecular genetics, and linkage studies in prostate cancer. *Prostate Suppl*. 1996;6:36-44. Review. PubMed PMID: 8630228.
10. Nelson JB, Lee WH, Nguyen SH, **Jarrard DF**, Brooks JD, Magnuson SR, Opgenorth TJ, Nelson WG, Bova GS. Methylation of the 5' CpG island of the endothelin B receptor gene is common in human prostate cancer. *Cancer Res*. 1997 Jan 1;57(1):35-7. PubMed PMID: 8988036.
11. Paul R, Ewing CM, **Jarrard DF**, Isaacs WB. The cadherin cell-cell adhesion pathway in prostate cancer progression. *Br J Urol*. 1997 Mar;79 Suppl 1:37-43. Review. PubMed PMID: 9088271.
12. **Jarrard DF**, Bova GS, Ewing CM, Pin SS, Nguyen SH, Baylin SB, Cairns P, Sidransky D, Herman JG, Isaacs WB. Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer. *Genes Chromosomes Cancer*. 1997 Jun;19(2):90-6. PubMed PMID: 9171999.
13. **Jarrard DF**, Paul R, van Bokhoven A, Nguyen SH, Bova GS, Wheelock MJ, Johnson KR, Schalken J, Bussemakers M, Isaacs WB. P-Cadherin is a basal cell-specific epithelial

- marker that is not expressed in prostate cancer. *Clin Cancer Res.* 1997 Nov;3(11):2121-8. PubMed PMID: 9815605.
14. Yeager TR, DeVries S, **Jarrard DF**, Kao C, Nakada SY, Moon TD, Bruskewitz R, Stadler WM, Meisner LF, Gilchrist KW, Newton MA, Waldman FM, Reznikoff CA. Overcoming cellular senescence in human cancer pathogenesis. *Genes Dev.* 1998 Jan 15;12(2):163-74. PubMed PMID: 9436977; PubMed Central PMCID: PMC316442.
 15. **Jarrard DF**, Kinoshita H, Shi Y, Sandefur C, Hoff D, Meisner LF, Chang C, Herman JG, Isaacs WB, Nassif N. Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. *Cancer Res.* 1998 Dec 1;58(23):5310-4. PubMed PMID: 9850055.
 16. **Jarrard DF**, Sarkar S, Shi Y, Yeager TR, Magrane G, Kinoshita H, Nassif N, Meisner L, Newton MA, Waldman FM, Reznikoff CA. p16/pRb pathway alterations are required for bypassing senescence in human prostate epithelial cells. *Cancer Res.* 1999 Jun 15;59(12):2957-64. PubMed PMID: 10383161.
 17. McDougall EM, Sosa RE, Gill IS, **Jarrard DF**. Controversial cases in endourology. *J Endourol.* 1999 Sep;13(7):465-9. PubMed PMID: 10569517.
 18. Kinoshita H, Shi Y, Sandefur C, **Jarrard DF**. Screening hypermethylated regions by methylation-sensitive single-strand conformational polymorphism. *Anal Biochem.* 2000 Feb 15;278(2):165-9. PubMed PMID: 10660458.
 19. Kinoshita H, Shi Y, Sandefur C, Meisner LF, Chang C, Choon A, Reznikoff CR, Bova GS, Friedl A, **Jarrard DF**. Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer. *Cancer Res.* 2000 Jul 1;60(13):3623-30. PubMed PMID: 10910077.
 20. Sarkar S, Jülicher KP, Burger MS, Della Valle V, Larsen CJ, Yeager TR, Grossman TB, Nickells RW, Protzel C, **Jarrard DF**, Reznikoff CA. Different combinations of genetic/epigenetic alterations inactivate the p53 and pRb pathways in invasive human bladder cancers. *Cancer Res.* 2000 Jul 15;60(14):3862-71. PubMed PMID: 10919661.
 21. Reznikoff CA, Sarkar S, Jülicher KP, Burger MS, Puthenveetil JA, **Jarrard DF**, Newton MA. Genetic alterations and biological pathways in human bladder cancer pathogenesis. *Urol Oncol.* 2000 Sep 1;5(5):191-203. PubMed PMID: 10973707.
 22. Nakada SY, Fadden P, **Jarrard DF**, Moon TD. Hand-assisted laparoscopic radical nephrectomy: comparison to open radical nephrectomy. *Urology.* 2001 Oct;58(4):517-20. PubMed PMID: 11597529.
 23. Han S, Starling JR, **Jarrard DF**. Indiana pouch urinary diversion for adenocarcinoma developing after ureterosigmoidostomy. *J Urol.* 2001 Oct;166(4):1391-2. PubMed PMID: 11547087.
 24. Schwarze SR, Shi Y, Fu VX, Watson PA, **Jarrard DF**. Role of cyclin-dependent kinase inhibitors in the growth arrest at senescence in human prostate epithelial and uroepithelial cells. *Oncogene.* 2001 Dec 13;20(57):8184-92. PubMed PMID: 11781834.
 25. Schwarze SR, DePrimo SE, Grabert LM, Fu VX, Brooks JD, **Jarrard DF**. Novel pathways associated with bypassing cellular senescence in human prostate epithelial cells. *J Biol Chem.* 2002 Apr 26;277(17):14877-83. PubMed PMID: 11836256.
 26. Nakada SY, Johnson DB, Hahnfield L, **Jarrard DF**. Resection of isolated fossa recurrence of renal-cell carcinoma after nephrectomy using hand-assisted laparoscopy. *J Endourol.* 2002 Nov;16(9):687-8. PubMed PMID: 12490025.
 27. **Jarrard DF**, Modder J, Fadden P, Fu V, Sebree L, Heisey D, Schwarze SR, Friedl A. Alterations in the p16/pRb cell cycle checkpoint occur commonly in primary and metastatic human prostate cancer. *Cancer Lett.* 2002 Nov 28;185(2):191-9. PubMed PMID: 12169393.

28. Bradley KA, Chappell R, Yuan Z, Odau H, Bruskewitz R, **Jarrard D**, Ritter MA. Erectile dysfunction and prostate brachytherapy doses to the penile bulb and neurovascular bundles. *Int J Radiat Oncol Biol Phys*. 2003. 1;57 (2 Suppl): S399-400.
29. Lee DK, Hinshaw M, Cripps D, **Jarrard DF**. Pyoderma gangrenosum of penis. *J Urol*. 2003 Jul;170(1):185-6. PubMed PMID: 12796681.
30. Schwarze SR, Fu VX, **Jarrard DF**. Cdc37 enhances proliferation and is necessary for normal human prostate epithelial cell survival. *Cancer Res*. 2003 Aug 1;63(15):4614-9. PubMed PMID: 12907640.
31. Atwood CS, Barzilai N, Bowen RL, Brown-Borg HM, **Jarrard DF**, Fu VX, Heilbronn LK, Ingram DK, Ravussin E, Schwartz RS, Weindruch R. Pennington scientific symposium on mechanisms and retardation of aging. *Exp Gerontol*. 2003 Oct;38(10):1217-26. PubMed PMID: 14580876.
32. Horwitz GJ, **Jarrard DF**. Extension of a shortened ureter using the in situ appendix during Indiana pouch urinary diversion. *Urology*. 2004 Jan;63(1):167-9. PubMed PMID: 14751375.
33. Fu VX, Schwarze SR, Kenowski ML, Leblanc S, Svaren J, **Jarrard DF**. A loss of insulin-like growth factor-2 imprinting is modulated by CCCTC-binding factor down-regulation at senescence in human epithelial cells. *J Biol Chem*. 2004 Dec 10;279(50):52218-26. PubMed PMID: 15471867.
34. Wilkin M, Horwitz G, Seetharam A, Hartenbach E, Schink JC, Bruskewitz R, **Jarrard DF**. Long-term complications associated with the Indiana pouch urinary diversion in patients with recurrent gynecologic cancers after high-dose radiation. *Urol Oncol*. 2005 Jan-Feb;23(1):12-5. PubMed PMID: 15885577.
35. **Jarrard DF**. Does zinc supplementation increase the risk of prostate cancer? *Arch Ophthalmol*. 2005 Jan;123(1):102-3. PubMed PMID: 15642820.
36. Schwarze SR, Luo J, Isaacs WB, **Jarrard DF**. Modulation of CXCL14 (BRAX) expression in prostate cancer. *Prostate*. 2005 Jun 15;64(1):67-74. PubMed PMID: 15651028.
37. Schwarze SR, Fu VX, Desotelle JA, Kenowski ML, **Jarrard DF**. The identification of senescence-specific genes during the induction of senescence in prostate cancer cells. *Neoplasia*. 2005 Sep;7(9):816-23. PubMed PMID: 16229804; PubMed Central PMCID: PMC1501939.
38. Faith D, Han S, Lee DK, Friedl A, Hicks JL, De Marzo AM, **Jarrard DF**. p16 is upregulated in proliferative inflammatory atrophy of the prostate. *Prostate*. 2005 Sep 15;65(1):73-82. PubMed PMID: 15880529.
39. Saleem M, Adhami VM, Zhong W, Longley BJ, Lin CY, Dickson RB, Reagan-Shaw S, **Jarrard DF**, Mukhtar H. A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. *Cancer Epidemiol Biomarkers Prev*. 2006 Feb;15(2):217-27. PubMed PMID: 16492908.
40. Aziz MH, Nihal M, Fu VX, **Jarrard DF**, Ahmad N. Resveratrol-caused apoptosis of human prostate carcinoma LNCaP cells is mediated via modulation of phosphatidylinositol 3-kinase/Akt pathway and Bcl-2 family proteins. *Mol Cancer Ther*. 2006 May;5(5):1335-41. PubMed PMID: 16731767.
41. Marshall JR, Sakr W, Wood D, Berry D, Tangen C, Parker F, Thompson I, Lippman SM, Lieberman R, Alberts D, **Jarrard D**, Coltman C, Greenwald P, Minasian L, Crawford ED. Design and progress of a trial of selenium to prevent prostate cancer among men with high-grade prostatic intraepithelial neoplasia. *Cancer Epidemiol Biomarkers Prev*. 2006 Aug;15(8):1479-84. PubMed PMID: 16896036.
42. Moore N, Laurila T, **Jarrard DF**. Sonographically documented stable seminoma: a case report. *Int Urol Nephrol*. 2007;39(4):1163-5. Epub 2007 Feb 28. PubMed PMID: 17333512.

43. Katz DA, **Jarrard DF**, McHorney CA, Hillis SL, Wiebe DA, Fryback DG. Health perceptions in patients who undergo screening and workup for prostate cancer. *Urology*. 2007 Feb;69(2):215-20. PubMed PMID: 17320653; PubMed Central PMCID: PMC1868466.
44. Johnson AR, Munoz A, Gottlieb JL, **Jarrard DF**. High dose zinc increases hospital admissions due to genitourinary complications. *J Urol*. 2007 Feb;177(2):639-43. PubMed PMID: 17222649.
45. Dobosy JR, Roberts JL, Fu VX, **Jarrard DF**. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia. *J Urol*. 2007 Mar;177(3):822-31. Review. PubMed PMID: 17296351.
46. Kibel AS, Rosenbaum E, Kattan MW, Picus J, Dreicer R, Klein EA, Chatta GS, Nelson JB, DiPaola RS, Roth BJ, Cookson MS, Wilding G, **Jarrard DF**, Beer TM, Ryan CW, Petrylak DP, Benson MC, Partin AW, Garrett-Mayer E, Eisenberger MA. Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. *J Urol*. 2007 May;177(5):1777-81. PubMed PMID: 17437819.
47. Best S, Sawers Y, Fu VX, Almassi N, Huang W, **Jarrard DF**. Integrity of prostatic tissue for molecular analysis after robotic-assisted laparoscopic and open prostatectomy. *Urology*. 2007 Aug;70(2):328-32. PubMed PMID: 17826499; PubMed Central PMCID: PMC2693382.
48. Allen GW, Howard AR, **Jarrard DF**, Ritter MA. Management of prostate cancer recurrences after radiation therapy-brachytherapy as a salvage option. *Cancer*. 2007 Oct 1;110(7):1405-16. Review. PubMed PMID: 17685384.
49. Sterrett SP, Laurila T, Bandi G, **Jarrard DF**. Identification and preservation of accessory pudendal vessels during robot-assisted laparoscopic radical retropubic prostatectomy. *Journal of Robotic Surgery* 2008; 2(1), 31-34.
50. Wong GW, Palazzi-Churas KL, **Jarrard DF**, Paolone DR, Graf AK, Hedican SP, Wegenke JD, Ritter MA. Salvage hypofractionated radiotherapy for biochemically recurrent prostate cancer after radical prostatectomy. *Int J Radiat Oncol Biol Phys*. 2008 Feb 1;70(2):449-55. PubMed PMID: 17869014.
51. Teng J, Wang ZY, **Jarrard DF**, Bjorling DE. Roles of estrogen receptor alpha and beta in modulating urothelial cell proliferation. *Endocr Relat Cancer*. 2008 Mar;15(1):351-64. PubMed PMID: 18310301; PubMed Central PMCID: PMC3513362.
52. Sterrett SP, **Jarrard DF**. Robotic assisted laparoscopic radical prostatectomy: evolution and outcomes. *Minerva Urol Nefrol*. 2008 Mar;60(1):31-9. Review. PubMed PMID: 18427433.
53. Safdar N, Abad CL, Kaul DR, **Jarrard D**, Saint S. Clinical problem-solving. An unintended consequence--a 79-year-old man with a 5-month history of fatigue and 20-lb (9-kg) weight loss presented to his local physician. *N Engl J Med*. 2008 Apr 3;358(14):1496-501. PubMed PMID: 18385502.
54. Ewald J, Desotelle J, Almassi N, **Jarrard D**. Drug-induced senescence bystander proliferation in prostate cancer cells in vitro and in vivo. *Br J Cancer*. 2008 Apr 8;98(7):1244-9. PubMed PMID: 18349844; PubMed Central PMCID: PMC2359629.
55. Ito F, **Jarrard D**, Gould JC. Transabdominal preperitoneal robotic inguinal hernia repair. *J Laparoendosc Adv Surg Tech A*. 2008 Jun;18(3):397-9. PubMed PMID: 18503373.
56. Dobosy JR, Fu VX, Desotelle JA, Srinivasan R, Kenowski ML, Almassi N, Weindrich R, Svaren J, **Jarrard DF**. A methyl-deficient diet modifies histone methylation and alters Igf2 and H19 repression in the prostate. *Prostate*. 2008 Aug 1; 68(11):1187-95. PubMed PMID: 18459101.
57. Fu VX, Dobosy JR, Desotelle JA, Almassi N, Ewald JA, Srinivasan R, Berres M, Svaren J, Weindrich R, **Jarrard DF**. Aging and cancer-related loss of insulin-like growth factor 2

- imprinting in the mouse and human prostate. *Cancer Res.* 2008 Aug 15; 68(16):6797-802. PubMed PMID: 18701505.
58. Warren M, Twohig M, Pier T, Eickhoff J, Lin CY, **Jarrard D**, Huang W. Protein expression of matriptase and its cognate inhibitor HAI-1 in human prostate cancer: a tissue microarray and automated quantitative analysis. *Appl Immunohistochem Mol Morphol.* 2009 Jan; 17(1):23-30. PubMed PMID: 18813126.
 59. Gee JR, **Jarrard DF**, Bruskewitz RC, Moon TD, Hedican SP, Leverson GE, Nakada SY, Messing EM. Reduced bladder cancer recurrence rate with cardioprotective aspirin after intravesical bacille Calmette-Guérin. *BJU Int.* 2009 Mar; 103(6):736-9. PubMed PMID: 19007364.
 60. Gee JR, Waterman BJ, **Jarrard DF**, Hedican SP, Bruskewitz RC, Nakada SY. Flexible and rigid cystoscopy in women. *JSLs.* 2009 Apr-Jun; 13(2):135-8. PubMed PMID: 19660204; PubMed Central PMCID: PMC3015938.
 61. Ewald JA, Peters N, Desotelle JA, Hoffmann FM, **Jarrard DF**. A high-throughput method to identify novel senescence-inducing compounds. *J Biomol Screen.* 2009 Aug;14(7):853-8. PubMed PMID: 19641224; PubMed Central PMCID: PMC2913693.
 62. Laurila TA, Huang W, **Jarrard DF**. Robotic-assisted laparoscopic and radical retropubic prostatectomy generates similar positive margin rates in low and intermediate risk patients. *Urol Oncol.* 2009 Sep-Oct; 27(5):529-33. PubMed PMID: 18640061.
 63. Quann P, **Jarrard DF**, Huang W. Current prostate biopsy protocols cannot reliably identify patients for focal therapy: correlation of low-risk prostate cancer on biopsy with radical prostatectomy findings. *Int J Clin Exp Pathol.* 2010 Mar 30;3(4):401-7. PubMed PMID: 20490330; PubMed Central PMCID: PMC2872746.
 64. Iskandar BJ, Rizk E, Meier B, Hariharan N, Bottiglieri T, Finnell RH, **Jarrard DF**, Banerjee RV, Skene JH, Nelson A, Patel N, Gherasim C, Simon K, Cook TD, Hogan KJ. Folate regulation of axonal regeneration in the rodent central nervous system through DNA methylation. *J Clin Invest.* 2010 May; 120(5):1603-16. PubMed PMID: 20424322; PubMed Central PMCID: PMC2860927.
 65. Bhusari SS, Dobosy JR, Fu V, Almassi N, Oberley T, **Jarrard DF**. Superoxide dismutase 1 knockdown induces oxidative stress and DNA methylation loss in the prostate. *Epigenetics.* 2010 Jul 1;5(5):402-9. PubMed PMID: 20458166.
 66. Ewald JA, Desotelle JA, Wilding G, **Jarrard DF**. Therapy-induced senescence in cancer. *J Natl Cancer Inst.* 2010 Oct 20; 102(20):1536-46. Review. PubMed PMID: 20858887; PubMed Central PMCID: PMC2957429.
 67. Patel SR, Kaplon DM, **Jarrard D**. A technique for the management of a large median lobe in robot-assisted laparoscopic radical prostatectomy. *J Endourol.* 2010 Dec;24(12):1899-901. PubMed PMID: 20858064.
 68. Kruser TJ, **Jarrard DF**, Graf AK, Hedican SP, Paolone DR, Wegenke JD, Liu G, Geyer HM, Ritter MA. Early hypofractionated salvage radiotherapy for postprostatectomy biochemical recurrence. *Cancer.* 2011 Jun 15; 117(12):2629-36. PubMed PMID: 21656740; PubMed Central PMCID: PMC3064951.
 69. King AC, Livermore A, Laurila TA, Huang W, **Jarrard DF**. Impact of immediate TRUS rebiopsy in a patient cohort considering active surveillance for favorable risk prostate cancer. *Urol Oncol.* 2011 Aug 2. PubMed PMID: 21816639.
 70. Marshall JR, Tangen CM, Sakr WA, Wood DP Jr, Berry DL, Klein EA, Lippman SM, Parnes HL, Alberts DS, **Jarrard DF**, Lee WR, Gaziano JM, Crawford ED, Ely B, Ray M, Davis W, Minasian LM, Thompson IM Jr. Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917. *Cancer Prev Res (Phila).* 2011 Nov;4(11):1761-9. PubMed PMID: 21896650; PubMed Central PMCID: PMC3208719.

71. Bhusari S, Yang B, Kueck J, Huang W, **Jarrard DF**. Insulin-like growth factor-2 (IGF2) loss of imprinting marks a field defect within human prostates containing cancer. *Prostate*. 2011 Nov;71(15):1621-30. PubMed PMID: 21432864.
72. Truong M, Yang B, Wagner J, Kobayashi Y, Rajamanickam V, Brooks J, **Jarrard DF**. Even-skipped homeobox 1 is frequently hypermethylated in prostate cancer and predicts PSA recurrence. *Br J Cancer*. 2012 Jun 26; 107(1):100-7. PubMed PMID: 22596233; PubMed Central PMCID: PMC3389415.
73. Ewald JA, **Jarrard DF**. Decreased skp2 expression is necessary but not sufficient for therapy-induced senescence in prostate cancer. *Transl Oncol*. 2012 Aug;5(4):278-87. PubMed PMID: 22937180; PubMed Central PMCID: PMC3431038.
74. Van Bogaert D, Hawkins R, Pingree S, **Jarrard D**. The Development of an eHealth tool suite for prostate cancer patients and their partners. *J Support Oncol*. 2012 Sep-Oct;10(5):202-8. PubMed PMID: 22591675.
75. Truong M, Yang B, Livermore A, Wagner J, Weeratunga P, Huang W, Dhir R, Nelson J, Lin DW, **Jarrard DF**. Using the Epigenetic Field Defect to Detect Prostate Cancer in Biopsy-Negative Patients. *J Urol*. 2012 Nov 15. PubMed PMID: 23159584. PMCID: PMC4226217.
76. Desotelle J, Truong M, Ewald J, Weeratunga P, Yang B, Huang W, **Jarrard D**. CpG island hypermethylation frequently silences FILIP1L isoform 2 expression in prostate cancer. *J Urol*. 2013 Jan;189(1):329-35. PubMed PMID: 23174249; PubMed Central PMCID: PMC3581042.
77. Truong M, Yang B, **Jarrard DF**. Toward the detection of prostate cancer in urine: a critical analysis. *J Urol*. 2013 Feb; 189(2):422-9. PubMed PMID: 23017522.
78. Truong M, Yang B, Wagner J, Desotelle J, **Jarrard DF**. Analysis of promoter non-CG methylation in prostate cancer. *Epigenomics*. 2013 Feb;5(1):65-71. PubMed PMID: 23414321.
79. Babaian K, Truong M, Cetnar J, Cross DS, Shi F, Ritter MA, **Jarrard DF**. Analysis of urological procedures in men who died from prostate cancer using a population-based approach. *BJU Int*. 2013 Mar;111(3 Pt B):E65-70. PubMed PMID: 23130676.
80. Ewald JA, Desotelle JA, Church DR, Yang B, Huang W, Laurila TA, **Jarrard DF**. Androgen deprivation induces senescence characteristics in prostate cancer cells in vitro and in vivo. *Prostate*. 2013 Mar;73(4):337-45. PubMed PMID: 22911222.
81. Slezak J, Truong M, Huang W, **Jarrard D**. HP1 γ expression is elevated in prostate cancer and is superior to Gleason score as a predictor of biochemical recurrence after radical prostatectomy. *BMC Cancer*. 2013 Mar 23;13:148. PubMed PMID: 23522301.
82. Yang B, Bhusari S, Kueck J, Weeratunga P, Wagner J, Levenson G, Huang W, **Jarrard DF**. Methylation profiling defines an extensive field defect in histologically normal prostate tissues associated with prostate cancer. *Neoplasia*. 2013 Apr;15(4):399-408. PubMed PMID: 23555185.
83. Gee J, Bailey H, Kim K, Kolesar J, Havighurst T, Tutsch KD, See W, Cohen MB, Street N, Levan L, **Jarrard D**, Wilding G. Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1 α -hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin. *Prostate*. 2013 Jun;73(9):970-8. PubMed PMID: 23335089.
84. Yang B, Wagner J, Yao T, Damaschke N, **Jarrard DF**. Pyrosequencing for the rapid and efficient quantification of allele-specific expression. *Epigenetics*. 2013 Aug 6;8(10). PubMed PMID: 23973940.
85. Damaschke NA, Yang B, Bhusari S, Svaren JP, **Jarrard DF**. Epigenetic susceptibility factors for prostate cancer with aging. *Prostate*. 2013 Sep 2. PubMed PMID: 23999928.

86. Truong M, Slezak JA, Lin CP, Iremashvili V, Sado M, Razmaria AA, Leverson G, Soloway MS, Eggener SE, Abel EJ, Downs TM, **Jarrard DF**. Development and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate cancer. *Cancer*. 2013 Nov 15;119(22):3992-4002. PubMed PMID: 24006289
87. Yang B, Wagner J, Damaschke N, Yao T, Wuerzberger-Davis SM, Lee MH, Svaren J, Miyamoto S, **Jarrard DF**. A Novel Pathway Links Oxidative Stress to Loss of Insulin Growth Factor-2 (IGF2) Imprinting through NF- κ B Activation. *PLoS One*. 2014 Feb 18;9(2): PubMed PMID: 24558376; PubMed Central PMCID: PMC3928145.
88. Abel EJ, Wong K, Sado M, Leverson GE, Patel SR, Downs TM, **Jarrard DF**. Surgical operative time increases the risk of deep venous thrombosis and pulmonary embolism in robotic prostatectomy. *JSLs*. 2014 Apr-Jun;18(2):282-7. PubMed PMID: 24960494; PubMed Central PMCID: PMC4035641.
89. Omernick KE, Abel EJ, Tevis SE, Shapiro DD, **Jarrard DF**, Kennedy GD, Downs TM. MP2-05 Identifying patients at high-risk for readmission after radical cystectomy using the national surgical quality improvement program database. *The Journal of Urology*;191(4):e26-e27. 2014 April
90. Abel EJ, Bauman T, Weiker M, Shi FF, Downs TM, **Jarrard DF**, Huang W. Analysis and validation of tissue biomarkers for renal cell carcinoma using automated high-throughput evaluation of protein expression. *Hum Pathol*. 2014 May; 45(5):1092-9. PubMed PMID: 24746216; PubMed Central PMCID: PMC4134351.
91. Yu YP, Ding Y, Chen Z, Liu S, Michalopoulos A, Chen R, Gulzar ZG, Yang B, Cieply KM, Luvison A, Ren BG, Brooks JD, **Jarrard DF**, Nelson JB, Michalopoulos GK, Tseng GC, Luo JH. Novel fusion transcripts associate with progressive prostate cancer. *Am J Pathol*. 2014 Oct;184(10):2840-9. PubMed PMID: 25238935; PubMed Central PMCID: PMC4188871.
92. Damaschke NA, Yang B, Blute ML Jr, Lin CP, Huang W, **Jarrard DF**. Frequent Disruption of Chromodomain Helicase DNA-Binding Protein 8 (CHD8) and Functionally Associated Chromatin Regulators in Prostate Cancer. *Neoplasia*. 2014 Dec;16(12):1018-27 PubMed PMID: 25499215. PubMed Central PMCID: PMC4309256.
93. Abel EJ, Linder BJ, Bauman TM, Bauer RM, Thompson RH, Thapa P, Devon ON, Tarrell RF, Frank I, **Jarrard DF**, Downs TM, Boorjian SA. Perioperative blood transfusion and radical cystectomy: does timing of transfusion affect bladder cancer mortality? *Eur Urol*. 2014 Dec;66(6):1139-47. PubMed PMID: 25194909.
94. **Jarrard DF**, Blute ML Jr, Ritter MA. Potential role for androgen-deprivation therapy and pelvic radiation therapy in node-positive postprostatectomy prostate cancer. *J Clin Oncol*. 2014 Dec 10;32(35):3926-9. PubMed PMID: 25332250.
95. Keil KP, Abler LL, Laporta J, Altmann HM, Yang B, **Jarrard DF**, Hernandez LL, Vezina CM. Androgen receptor DNA methylation regulates the timing and androgen sensitivity of mouse prostate ductal development. *Dev Biol*. 2014 Dec 15;396(2):237-45. PubMed PMID: 25446526; PubMed Central PMCID: PMC4261055.
96. Blute ML Jr, Damaschke NA, **Jarrard DF**. The epigenetics of prostate cancer diagnosis and prognosis: update on clinical applications. *Curr Opin Urol*. 2015 Jan;25(1):83-8. PubMed PMID: 25405932.
97. Wagner J, Damaschke N, Truong M, Yang B, Guenther C, Huang W, **Jarrard DF**. Overexpression of the Novel Senescence Marker β -Galactosidase (GLB1) in Prostate Cancer Predicts Reduced PSA Recurrence. *PLoS One*. 2015 Apr 15;10(4):e0124366 PubMed PMID: 25876105; PubMed Central PMCID: PMC4398352.

98. Yang B, Damaschke N, Yao T, McCormick J, Wagner J, **Jarrard D**. Pyrosequencing for accurate imprinted allele expression analysis. *J Cell Biochem*. 2015 Jul;116(7):1165-70. PubMed PMID: 25581900; PubMed Central PMCID: PMC4880354.
99. Blute, Jr. ML, Rushmer TJ, Shi F, Fuller BJ, Abel EJ, **Jarrard DF**, Downs TM. Renin-Angiotensin Inhibitors Decrease Recurrence after Transurethral Resection of Bladder Tumor in Nonmuscle Invasive Bladder Cancer. *J Urol*. 2015 Jul 11.
100. Blute ML Jr, Abel EJ, Downs TM, Kelcz F, **Jarrard DF**. Addressing the need for repeat prostate biopsy: new technology and approaches. *Nat Rev Urol*. 2015 Aug;12(8):435-44. Review. PubMed PMID: 26171803.
101. Sweeney CJ, Chen YH, Carducci M, Liu G, **Jarrard DF**, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. *N Engl J Med*. 2015 Aug 20;373(8):737-46. PubMed PMID: 26244877; PubMed Central PMCID: PMC4562797.
102. Abel EJ, Heckman JE, Hinshaw L, Best S, Lubner M, **Jarrard DF**, Downs TM, Nakada SY, Lee FT Jr, Huang W, Ziemlewicz T. Multi-quadrant biopsy technique improves diagnostic ability in large heterogeneous renal masses. *J Urol*. 2015 Oct;194(4):886-891. PubMed PMID: 25837535.
103. Blute ML Jr, Rushmer TJ, Shi F, Fuller BJ, Abel EJ, **Jarrard DF**, Downs TM. Renin-Angiotensin Inhibitors Decrease Recurrence after Transurethral Resection of Bladder Tumor in Patients with Nonmuscle Invasive Bladder Cancer. *J Urol*. 2015 Nov;194(5):1214-9. PubMed PMID: 26173101.
104. Wojcieszynski AP, **Jarrard DF**, Graf AK, Saha S, Kruser TJ, Ritter MA. Long-term Efficacy and Toxicity of Hypofractionated Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer. *International Journal of Radiation Oncology • Biology • Physics*;93(3):E186. November 2015
105. Kelcz F, **Jarrard DF**. Prostate cancer: The applicability of textural analysis of MRI for grading. *Nat Rev Urol*. 2016 Apr;13(4):185-6. PubMed PMID: 26878802.
106. Gee JR, Saltzstein DR, Messing E, Kim K, Kolesar J, Huang W, Havighurst TC, Harris L, Wollmer BW, **Jarrard D**, House M, Parnes H, Bailey HH. Phase Ib placebo-controlled, tissue biomarker trial of diindolylmethane (BR-DIMNG) in patients with prostate cancer who are undergoing prostatectomy. *Eur J Cancer Prev*. 2016 Jul; 25(4):312-20. PubMed PMID: 26313229.
107. Blute ML Jr, Zorn K, Grimes M, Shi F, Downs TM, **Jarrard DF**, Best SL, Richards K, Nakada SY, Abel EJ. Extreme obesity does not predict poor cancer outcomes after surgery for renal cell cancer. *BJU Int*. 2016 Sep;118(3):399-407. PubMed PMID: 26589741.
108. **Jarrard D**, Konety B, Huang W, Downs T, Kolesar J, Kim KM, Havighurst T, Slaton J, House MG, Parnes HL, Bailey HH. Phase IIa, randomized placebo-controlled trial of single high dose cholecalciferol (vitamin D(3)) and daily Genistein (G-2535) versus double placebo in men with early stage prostate cancer undergoing prostatectomy. *Am J Clin Exp Urol*. 2016 Sep 20;4(2):17-27. PubMed PMID: 27766277; PubMed Central PMCID: PMC5069272.
109. Grimes MD, Blute ML, Wittmann TA, Mann MA, Zorn K, Downs TM, Shi F, **Jarrard DF**, Best SL, Richards KA, Nakada SY, Abel EJ. A Critical Analysis of Perioperative

- Outcomes in Morbidly Obese Patients Following Renal Mass Surgery. *Urology*. 2016 Oct; 96: 93-98. PubMed PMID: 27339026.
110. Heninger E, Krueger TE, Thiede SM, Sperger JM, Byers BL, Kircher MR, Kosoff D, Yang B, **Jarrard DF**, McNeel DG, Lang JM. Inducible expression of cancer-testis antigens in human prostate cancer. *Oncotarget*. 2016 Dec 20;7(51):84359-84374. PubMed PMID: 27769045; PubMed Central PMCID: PMC5341296.
 111. Blute ML Jr, Ziemlewicz TJ, Lang JM, Kyriakopoulos C, **Jarrard DF**, Downs TM, Grimes M, Shi F, Mann MA, Abel EJ. Metastatic Tumor Burden Does Not Predict Overall Survival Following Cytorreductive Nephrectomy for Renal Cell Carcinoma: a Novel 3-Dimensional Volumetric Analysis. *Urology*. 2017 Feb;100:139-144. PubMed PMID: 27667156.
 112. Blute ML Jr, Damaschke N, Wagner J, Yang B, Gleave M, Fazli L, Shi F, Abel EJ, Downs TM, Huang W, **Jarrard DF**. Persistence of senescent prostate cancer cells following prolonged neoadjuvant androgen deprivation therapy. *PLoS One*. 2017 Feb 24;12(2):e0172048. PubMed PMID: 28234906; PubMed Central PMCID: PMC5325224.
 113. Jay R, Heckman JE, Hinshaw L, Best S, Lubner M, Jarrard DF, Downs TM, Nakada SY, Lee FT Jr, Huang W, Ziemlewicz TJ. Multi-quadrant biopsy technique improves diagnostic ability in large heterogeneous renal masses. *Urol Oncol*. 2017 Mar;35(3):119. PubMed PMID: 28159492.
 114. Tazeh NN, Canter DJ, Damodaran S, Rushmer T, Richards KA, Abel EJ, **Jarrard DF**, Downs TM. Neutrophil to Lymphocyte Ratio (NLR) at the Time of Transurethral Resection of Bladder Tumor: A Large Retrospective Study and Analysis of Racial Differences. *Bladder Cancer*. 2017 Apr 27;3(2):89-94. PubMed PMID: 28516153; PubMed Central PMCID: PMC5409044.
 115. Blute ML Jr, Kucherov V, Rushmer TJ, Damodaran S, Shi F, Jason Abel E, **Jarrard DF**, Richards KA, Messing EM, Downs TM. Reduced Estimated Glomerular Filtration Rate (eGFR <60 ml/min) at First Transurethral Resection of Bladder Tumor is a Significant Predictor of Subsequent Recurrence and Progression. *BJU Int*. 2017 May 2. PubMed PMID: 28464520.
 116. Blute ML Jr, Shiao JM, Truong M, Shi F, Abel EJ, Downs TM, **Jarrard DF**. A biopsy-integrated algorithm for determining Gleason 6 upgrading risk stratifies risk of active surveillance failure in prostate cancer. *World J Urol*. 2017 May;35(5):729-735. PubMed PMID: 27631325.
 117. Lee J-H, Yang BH, Damaschke NH, Boersma MD, Huang WH, Corey E, **Jarrard DF**, Denu JM. Identifying dysregulated epigenetic enzymes in castrate-resistant prostate cancer development. *The FASEB Journal*. 2017;31(1 Supplement):755.14.
 118. Wang JH, Downs TM, Jason Abel E, Richards KA, **Jarrard DF**. Prostate Biopsy in Active Surveillance Protocols: Immediate Re-biopsy and Timing of Subsequent Biopsies. *Curr Urol Rep*. 2017 Jul;18(7):48. Review. PubMed PMID: 28589399.
 119. Blute ML Jr, Kucherov V, Rushmer TJ, Damodaran S, Shi F, Abel EJ, **Jarrard DF**, Richards KA, Messing EM, Downs TM. Reduced estimated glomerular filtration rate (eGFR <60 mL/min/1.73 m²) at first transurethral resection of bladder tumour is a significant predictor of subsequent recurrence and progression. *BJU Int*. 2017 Sep;120(3):387-393. PubMed PMID: 28464520.

120. Damaschke N, Yang B, Bhusari S, Avilla M, Zhong W, Blute ML Jr, Huang W, **Jarrard DF**. Insulin-like Growth Factor 2 Loss of Imprinting Engineered Using CTCF Binding Site Mutations Promotes Widespread Neoplastic Growth in the Prostate. *Cancer Res*. 2017 Oct 1;77(19):5236-5247. PMID:28775169
121. Damodaran S, Kyriakopoulos CE, **Jarrard DF**. Newly diagnosed metastatic prostate cancer- has the paradigm changed? *Urol Clin North Am*. 2017 Nov;44(4):611-621. PMID: 29107277
122. Maciolek KA, **Jarrard DF**, Abel EJ, Best SL. Systematic Assessment Reveals Lack of Understandability for Prostate Biopsy Online Patient Education Materials. *Urology*. 2017 Nov;109:101-106. PubMed PMID: 28780302.
123. Lee JH, Yang B, Lindahl AJ, Damaschke N, Boersma MD, Huang W, Corey E, **Jarrard DF**, Denu JM. Identifying Dysregulated Epigenetic Enzyme Activity in Castrate-Resistant Prostate Cancer Development. *ACS Chem Biol*. 2017 Nov 17;12(11):2804-2814. PubMed PMID: 28949514
124. Harshman LC, Chen YH, Liu G, Carducci MA, **Jarrard D**, Dreicer R, Hahn N, Garcia JA, Hussain M, Shevrin D, Eisenberger M, Kohli M, Plimack ER, Cooney M, Vogelzang NJ, Picus J, DiPaola R, Sweeney CJ; ECOG-ACRIN 3805 Investigators. Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone Sensitive Prostate Cancer Treated With Androgen Deprivation With Or Without Docetaxel. *J Clin Oncol*. 2017 Dec 20;JCO2017753921. PubMed PMID: 29261442
125. Damodaran S, Damaschke N, Gawdzik J, Yang B, Shi C, Allen GO, Huang W, Denu J, **Jarrard D**. Dysregulation of Sirtuin 2 (SIRT2) and histone H3K18 acetylation pathways associates with adverse prostate cancer outcomes. *BMC Cancer*. 2017 Dec 20;17(1):874. PubMed PMID: 29262808; PubMed Central PMCID: PMC5738829.
126. Johnson BP, Vitek RA, Geiger PG, Huang W, **Jarrard DF**, Lang JM and Beebe DJ. Vitral ex-vivo tissue labeling and pathology-guided micropunching to characterize cellular heterogeneity in the tissue microenvironment. *BioTechniques* 2018 Jan; 64 (1): 13-19.
127. Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, **Jarrard DF**, Hahn NM, Shevrin DH, Dreicer R, Hussain M, Eisenberger M, Kohli M, Plimack ER, Vogelzang NJ, Picus J, Cooney MM, Garcia JA, DiPaola RS, Sweeney CJ. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. *J Clin Oncol*. 2018 Jan 31;JCO2017753657. PubMed PMID: 29384722.
128. Sierra PS, Damodaran S, **Jarrard D**. Clinical and pathologic factors predicting reclassification in active surveillance cohorts. *Int Braz J Urol*. 2018 Jan 26;44. PubMed PMID: 29368876.
129. Morgans AK, Chen YH, Sweeney CJ, **Jarrard DF**, Plimack ER, Gartrell BA, Carducci MA, Hussain M, Garcia JA, Cella D, DiPaola RS, Patrick-Miller LJ. Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer. *J Clin Oncol*. 2018 Mar 9;JCO2017753335. PubMed PMID: 29522362.
130. Harshman LC, Chen YH, Liu G, Carducci MA, **Jarrard D**, Dreicer R, Hahn N, Garcia JA, Hussain M, Shevrin D, Eisenberger M, Kohli M, Plimack ER, Cooney M, Vogelzang NJ, Picus J, DiPaola R, Sweeney CJ. Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen

- Deprivation With or Without Docetaxel. *J Clin Oncol*. 2018 Feb 1;36(4):376-382. Epub 2017 Dec 20. PubMed PMID: 29261442; PubMed Central PMCID: PMC5805480.
131. Gravis G, Boher JM, Chen YH, Liu G, Fizazi K, Carducci MA, Oudard S, Joly F, **Jarrard D**, Soulie M, Eisenberger MJ, Habibian M, Dreicer R, Garcia JA, Hussain MHM, Kohli M, Vogelzang NJ, Picus J, DiPaola R, Sweeney C. Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel. *Eur Urol*. 2018 Feb 20. PubMed PMID: 29475737.
 132. Richards KA, Ruiz VL, Murphy DR, Downs TM, Abel EJ, **Jarrard DF**, Singh H. Diagnostic evaluation of patients presenting with hematuria: An electronic health record-based study. *Urol Oncol*. 2018 Mar;36(3):88.e19-88.e25. PubMed PMID: 29169843.
 133. Cesnik AJ, Yang B, Truong A, Etheridge T, Spiniello M, Steinbrink MI, Shortreed MR, Frey BL, **Jarrard DF**, Smith LM. Long Noncoding RNAs and Newly Discovered XPLAID Differentiate Aggressive and Indolent Prostate Cancers. *Transl Oncol*. 2018 Jun;11(3):808-814. PubMed PMID: 29723810.
 134. Spiniello M, Knoener RA, Steinbrink MI, Yang B, Cesnik AJ, Buxton KE, Scalf M, **Jarrard DF**, Smith LM. HyPR-MS for Multiplexed Discovery of MALAT1, NEAT1, and NORAD lncRNA Protein Interactomes. *J Proteome Res*. 2018 Sep 7;17(9):3022-3038. PubMed PMID: 29972301.
 135. Etheridge T, Liou J, Downs TM, Abel EJ, Richards KA, **Jarrard DF**. The impact of celecoxib on outcomes in advanced prostate cancer patients undergoing androgen deprivation therapy. *Am J Clin Exp Urol*. 2018 Jun 15;6(3):123-132. PubMed PMID: 30038944; PubMed Central PMCID: PMC6055075.
 136. Richards KA, Liou JI, Cryns VL, Downs TM, Abel EJ, **Jarrard DF**. Metformin Use Is Associated With Improved Survival in Patients with Advanced Prostate Cancer on Androgen Deprivation Therapy. *J Urol*. 2018 Jun 22. PubMed PMID: 2994025
 137. Lowrance WT, Murad MH, Oh WK, **Jarrard DF**, Resnick MJ, Cookson MS. Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2018. *J Urol*. 2018 Aug 4. pii: S0022-5347(18)43671-3. PubMed PMID: 30086276.
 138. Maciolek KA, Best SL, Lopez V, Posielski N, Knoedler M, Bushman WA, **Jarrard DF**, Downs TM, Abel EJ, Richards KA. Effectiveness of a transrectal prostate needle biopsy protocol with risk-tailored antimicrobials in a veteran's cohort. *Urol Oncol*. 2018 Aug;36(8):363.e13-363.e20.
 139. Etheridge T, Liou JI, Downs TM, Abel EJ, **Jarrard DF** and Richards KA. The Impact of Agent Orange on Prostate Cancer Outcomes. *Urol*. 2018 Oct 12. PMID 30321553
 140. Etheridge T, Straus J, Ritter MA, **Jarrard DF**, and Huang W. Semen AMACR Protein as a Novel Method for Detecting Prostate Cancer. *Urol Oncol*. 2018 Oct 15. PMID: 30337219
 141. Anderson-Carter I, Posielski N, Liou JI, Khemees TA, Downs TM, Abel EJ, **Jarrard DF**, Richards KA. The impact of statins in combination with androgen deprivation therapy in patients with advanced prostate cancer: A large observational study. *Urol Oncol*. 2018 [Epub ahead of print] PMID: 30528885
 142. Etheridge T, Damodaran S, Schultz A, Richards KA, Gawdzik J, Yang B, Cryns V, **Jarrard DF**. Combination therapy with androgen deprivation for hormone sensitive prostate cancer: A new frontier. *Asian J Urol*. 2019 Jan;6(1):57-64. Epub 2018 Sep 15. Review. PubMed PMID: 30775249; PubMed Central PMCID: PMC6363606.
 143. Wang JH, Sierra P, Richards KA, Abel EJ, Allen GO, Downs TM, **Jarrard DF**. Impact of bilateral biopsy-detected prostate cancer on an active surveillance population. *BMC Urol*. 2019 Apr 23;19(1):26. PubMed PMID: 31014300; PubMed Central PMCID: PMC6480830.

144. Damodaran S, Lang JM, **Jarrard DF**. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches. *J Urol*. 2019 May;201(5):876-885. Review. PubMed PMID: 30747897.
145. Jarrard WE, Schultz A, Etheridge T, Damodaran S, Allen GO, **Jarrard D**, Yang B. Screening of urine identifies PLA2G16 as a field defect methylation biomarker for prostate cancer detection. *PLoS One*. 2019 Jun 24;14(6):e0218950. PubMed PMID: 31233548; PubMed Central PMCID: PMC6590820.
146. Rutkowski DR, Wells SA, Johnson B, Huang W, **Jarrard DF**, Lang JM, Cho S, Roldán-Alzate A. MRI-based cancer lesion analysis with 3d printed patient specific prostate cutting guides. *Am J Clin Exp Urol*. 2019 Aug 15;7(4):215-222. PubMed PMID: 31511828; PubMed Central PMCID: PMC6734042.
147. Yu J, Berthier E, Craig A, de Groot TE, Sparks S, Ingram PN, **Jarrard DF**, Huang W, Beebe DJ, Theberge AB. Reconfigurable open microfluidics for studying the spatiotemporal dynamics of paracrine signalling. *Nature Biomed Eng*. 2019 Oct;3(10):830-841. Epub 2019 Aug 19. PubMed PMID: 31427781.
148. Yang B, Etheridge T, McCormick J, Schultz A, Khemees TA, Damaschke N, Levenson G, Woo K, Sonn GA, Klein EA, Fumo M, Huang W, **Jarrard DF**. Validation of an epigenetic field of susceptibility to detect significant prostate cancer from non-tumor biopsies. *Clin Epigenetics*. 2019 Nov 28;11(1):168. PMID: 31779677; PMCID: PMC6883627.
149. Shapiro DD, Wells SA, Best SL, Hedican SP, Ziemlewicz TJ, Lubner MG, Hinshaw JL, Lee FT Jr, **Jarrard DF**, Richards KA, Downs TM, Allen GO, Nakada SY, Abel EJ. Comparing Outcomes for Patients with Clinical T1b Renal Cell Carcinoma Treated With Either Percutaneous Microwave Ablation or Surgery. *Urology*. 2020 Jan;135:88-94. PMID: 31585198.
150. Miller BL, Abel EJ, Allen G, Schumacher JR, **Jarrard D**, Downs T, Richards KA. Trends in epidural anesthesia use at the time of radical cystectomy and its association with perioperative and survival outcomes: a population-based analysis. *Am J Clin Exp Urol*. 2020 Feb 25;8(1):28-37. PMID: 32211451; PMCID: PMC7076291.
151. Hearn JWD, Sweeney CJ, Almassi N, Reichard CA, Reddy CA, Li H, Hobbs B, **Jarrard DF**, Chen YH, Dreicer R, Garcia JA, Carducci MA, DiPaola RS, Sharifi N. HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer. *JAMA Oncol*. 2020 Apr 1;6(4):e196496. PMID: 32053149; PMCID: PMC7042830.
152. Damaschke NA, Gawdzik J, Avilla M, Yang B, Svaren J, Roopra A, Luo JH, Yu YP, Keles S, **Jarrard DF**. CTCF loss mediates unique DNA hypermethylation landscapes in human cancers. *Clin Epigenetics*. 2020 Jun 5;12(1):80. PMID: 32503656; PMCID: PMC7275597.
153. Bukowy JD, Foss H, McGarry SD, Lowman AK, Hurrell SL, Iczkowski KA, Banerjee A, Bobholz SA, Barrington A, Dayton A, Unteriner J, Jacobsohn K, See WA, Nevalainen MT, Nencka AS, Etheridge T, **Jarrard DF**, LaViolette PS. Accurate segmentation of prostate cancer histomorphometric features using a weakly supervised convolutional neural network. *J Med Imaging (Bellingham)*. 2020 Sep;7(5):057501 PMID: 33062803; PMCID: PMC7550797.

154. Yang B, Damodaran S, Khemees TA, Filon MJ, Schultz A, Gawdzik J, Etheridge T, Malin D, Richards KA, Cryns VL, **Jarrard DF**. Synthetic Lethal Metabolic Targeting of Androgen Deprived Prostate Cancer Cells with Metformin. *Mol Cancer Ther*. 2020 Sept PMID: 32943543.
155. Bryce AH, Chen YH, Liu G, Carducci MA, **Jarrard DM**, Garcia JA, Dreicer R, Hussain M, Eisenberger MA, Plimack ER, Vogelzang NJ, DiPaola RS, Harshman L, Sweeney CJ. Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHARTED Trial. *Eur Urol Oncol*. 2020 Dec;3(6):717-724. PMID: 32807727; PMCID: PMC7738423.
156. Luo JH, Liu S, Tao J, Ren BG, Luo K, Chen ZH, Nalesnik M, Cieply K, Ma T, Cheng SY, Chen Q, Michalopoulos GK, Nelson JB, Bhargava R, Zhang J, Ma D, **Jarrard D**, Pennathur A, Luketich JD, DeFranco DB, Monga SP, Tseng G, Yu YP. Pten-NOLC1 fusion promotes cancers involving MET and EGFR signalings. *Oncogene*. 2020 Dec 15. PMID: 33323972.
157. Lowrance WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R, **Jarrard DF**, Kibel AS, Morgan TM, Morgans AK, Oh WK, Resnick MJ, Zietman AL, Cookson MS. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I. *J Urol*. 2021 Jan;205(1):14-21 PMID: 32960679.
158. Lowrance WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R, **Jarrard DF**, Kibel AS, Morgan TM, Morgans AK, Oh WK, Resnick MJ, Zietman AL, Cookson MS. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II. *J Urol*. 2021 Jan;205(1):22-29. PMID: 32960678.
159. **Jarrard D**, Filon M, Huang W, Havighurst T, DeShong K, Kim K, Konety BR, Saltzstein D, Mukhtar H, Wollmer B, Suen C, House MG, Parnes HL, Bailey HH. A phase II randomized placebo-controlled trial of pomegranate fruit extract in men with localized prostate cancer undergoing active surveillance. *Prostate*. 2021 Jan;81(1):41-49. PMID: 33095939.
160. Yu J, Piazza A, Sparks S, Hind LE, Niles DJ, Ingram PN, Huang W, Ricke WA, **Jarrard DF**, Huttenlocher A, Basu H, Beebe DJ. A reconfigurable microscale assay enables insights into cancer-associated fibroblast modulation of immune cell recruitment. *Integr Biol (Camb)*. 2021 Apr 20;13(4):87-97. PMID: 33822934.
161. Posielski NM, Richards KA, Liou JI, Borza T, Abel EJ, Downs TM, **Jarrard DF**. Beta-Adrenergic Antagonists and Cancer Specific Survival in Patients With Advanced Prostate Cancer: A Veterans Administration Cohort Study. *Urology*. 2021 Feb 13:S0090-4295(21)00173-4. Epub ahead of print. PMID: 33587939.
162. Borza T, Greenberg C, **Jarrard DF**, Jacobs B and Hollenbeck B. Cystectomy Readmissions and the Opioid Epidemic: An Opportunity for Synergistic Improvement Urologic Oncology: Seminars and Original Investigations. (*In Press*)
163. Boorjian SA, Masterson TA, **Jarrard DF**, Gore JL, Abel EJ, Karam JA, Kutikov A, Morgan T, Porten S, and Evans CP. Survey of SUO Fellowship Graduates on Early-Career Perspectives Substantiates Training Benefits. *Urologic Oncology*. (*In Press*)
164. Filon M, Gawdzik J, Truong A, Allen G, Huang W, Khemees T, Machhi R, Lewis P, Yang B, Denu J, and **Jarrard DF**. Tandem histone methyltransferase upregulation defines a unique aggressive prostate cancer phenotype. *Br J Can*. 2021 Jul. PMID: 33976366

165. Heninger E, Kosoff D, Rodems TS, Sethakorn N, Singh A, Gungurthi H, Carlson KN, Yang B, Gilsdorf C, Pasch CA, Deming DA, Ellis L, Beebe DJ, **Jarrard DF**, Lang JM. Live cell molecular analysis of primary prostate cancer organoids identifies persistent androgen receptor signaling. *Med Oncol*. 2021 Sep 28;38(11):135. PMID: 34581895.
166. Hubbard S, Wells SA, Olson K, **Jarrard DF**, Huang W. Combined mpMRI/US fusion targeted and concurrent standard biopsies in the detection of prostate cancer: a retrospective study. *Am J Transl Res*. 2021 Oct 15;13(10):12107-12113. PMID: 34786148.
167. Kheemes TA, Yang B, Schultz A, Allen GO, Gawdzik J, Nihal A, Richards KA, Abel EJ, **Jarrard DF**. Epigenetic field alterations in non-tumor prostate tissues detect prostate cancer in urine. *Am J Clin Exp Urol*. 2021 Dec 15;9(6):479-488. PMID: 34993267
168. Carr AV, Frey BL, Scalf M, Cesnik AJ, Rolfs Z, Pike KA, Yang B, Keller MP, **Jarrard DF**, Shortreed MR, Smith LM. MetaNetwork Enhances Biological Insights from Quantitative Proteomics Differences by Combining Clustering and Enrichment Analyses. *J Proteome Res*. 2022 Jan 24. PMID: 35073098.
169. Rodems TS, Heninger E, Stahlfeld CN, Gilsdorf CS, Carlson KN, Kircher MR, Singh A, Krueger TEG, Beebe DJ, **Jarrard DF**, McNeel DG, Haffner MC, Lang JM. Reversible epigenetic alterations regulate class I HLA loss in prostate cancer. *Commun Biol*. 2022 Sep 1; 5(1): doi: 10.1038/s42003-022-03843-6. PMID: 36050516.
170. Morgans AK, Chen YH, **Jarrard DF**, Carducci M, Liu G, Eisenberger M, Plimack ER, Bryce A, Garcia JA, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, DiPaola RS, Cella D, Sweeney CJ; ECOG-ACRIN E3805 Investigators. *Prostate*. 2022 Sep;82(12):1176-1185:doi 10.1002/pros.24369. Epub 2022 May 10. PMID 35538398.
171. Sethakorn N, Heninger E, Breneman MT, Reccia E, Ding AB, **Jarrard DF**, Hematti P, Beebe DJ, Kosoff D. Integrated analysis of the tumor microenvironment using a reconfigurable microfluidic cell culture platform. *FASEB J*. 2022 Oct; 36(10):e22540.doi:10.1096/fj.202200684RR.
172. Filon MJ, Gillette AA, Yang B, Kheemes TA, Skala MC, **Jarrard DF**. Prostate cancer cells demonstrate unique metabolism and substrate adaptability acutely after androgen deprivation therapy. *Prostate*. 2022 Dec;82(16):1547-1557. doi: 10.1002/pros.24428. Epub 2022 Aug 18.
173. Dreicer LW, **Jarrard DF**, Scarpato KR, Kim SK, Kirkby E, Budkley DI, Griffin JC, Cookson MS. Updates to Advanced Prostate Cancer: AUA/SUO Guidelines (2023). *J Urology* 2023; Jun:209(6)1082-1090. PMID:37096583.
174. Whitworth IT, Henke KB, Yang B, Scalf M, Frey BL, **Jarrard DF**, Smith LM. Elucidating the RNA-Protein interactomes of Target RNAs in Tissue. *Anal Chem*. 2023 May 9;95(18):7087-7092. doi: 10.1021/acs.analchem.2c05635. Epub 2023 Apr 24. PMID: 37093976
175. Moses KA, Sprengle PC, Bahler C, Box G, Carlsson SV, Catalona WJ, Dahl DM, Dall'Era M, Davis JW, Drake BF, Epstein JI, Etzioni RB, Farrington TA, Garraway IP, **Jarrard D**, Kauffman E, Kaye D, Kibel AS, LaGrange CA, Maroni P, Ponsky L, Reys B, Salami SS, Sanchez A, Seibert TM, Shaneyfelt TM, Smaldone MC, Sonn G, Tyson MD, Vapiwala N, Wake R, Washington S, Yu A, Yuh B, Berardi RA, Freedman-Cass DA. NCCN Guidelines® Insights: Prostate Cancer Early Detection, Version 1.2023. *J Natl*

- Compr Canc Netw.* 2023 Mar;21(3):236-246. doi: 10.6004/jnccn.2023.0014.PMID: 36898362
176. Yu YP, Liu S, Ren BG, Nelson J, **Jarrard D**, Brooks JD, Michalopoulos G, Tseng G, Luo JH. Fusion Gene Detection in Prostate Cancer Samples Enhances the Prediction of Prostate Cancer Clinical Outcomes from Radical Prostatectomy through Machine Learning in a Multi-Institutional Analysis. *Am J Pathol.* 2023: Apr; 193(4) 392-403: doi 10.1016/j.ajpath.2022.12.013. Epub 2023 Jan 18. PMID 36681188.
177. Filon M, Yang B, Purohit TA, Schehr J, Singh A, Bigarella M, Lewis P, Denu J, Lang J, **Jarrard DF**. Development of a multiplex assay to assess activated p300/CBP in circulating prostate tumor cells. *Oncotarget.* 2023 Jul 20;14:738-746. doi: 10.18632/oncotarget.28477.PMID: 37477521
178. Penn T, Borza T, Liou JI, Jason Abel E, Shapiro DD, **Jarrard DF**, Ricke WA, Richards KA. The Impact of Agent Orange Exposure on Non-Muscle Invasive Bladder Cancer Outcomes. *Urology.* 2023 Sep 18:S0090-4295(23)00794-X. doi: 10.1016/j.urology.2023.08.037. Online ahead of print.PMID: 37730166

Editorial Comments/Special Communications

1. **Jarrard DF**. More data on locally extensive prostate cancer--betting on the margin. *J Urol*. 2000 Apr; 163(4):1189-90. PubMed PMID: 10737492.
2. **Jarrard DF**. Change in prostate cancer grade over time in men followed expectantly for stage T1c disease. *J Urol*. 2008 Mar; 179(3): discussion 904-5.
3. **Jarrard DF**, Huang W. The New Age of Molecular Taxonomy Approaches. *Eur Urol*. 2016 Apr; 69(4):561-2. PubMed PMID: 26626616.
4. **Jarrard DF**. Commentary: "Impact of Local Treatment on Overall Survival in Patients with Metastatic Prostate Cancer on Diagnosis", *Practice Update*(www.practiceupdate.com) 2017
5. **Jarrard DF**. Commentary: "Effect of Abiraterone Acetate and Prednisone on PSA and Radiographic Disease Progression in Patients With Non-Metastatic Castration-Resistant Prostate Cancer' *Practice Update*(www.practiceupdate.com). May 2018
6. **Jarrard DF**. Commentary: "Effect of Abiraterone Acetate and Prednisone on PSA and Radiographic Disease Progression in Patients With Non-Metastatic Castration-Resistant Prostate Cancer' *Practice Update*(www.practiceupdate.com). October 2018
7. **Jarrard DF**. TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer. *PracticeUpdate website*. Available at: (<https://www.practiceupdate.com>) April 12, 2019
8. **Jarrard DF**. Novel strategy to improve prostate cancer treatment using inexpensive, common non-cancer drugs. *Doximity* Sept 14, 2020
9. **Jarrard DF**. Drug intervention for active surveillance with Apalutamide: The patient comes first. *Doximity* Dec 5 2020
10. **Jarrard DF**. 'Update on ADT and its side-effects in advanced prostate cancer'. *Urology Times* (video and print) April 2022.

Book Chapters

1. Yeager TR, **Jarrard DF**, and Reznikoff CA. An *in vitro* model of bladder cancer pathogenesis. In: Adolph KW, ed. *Human Genome*. CRC Press, 160-180, 1998.
2. Wilkins M and **Jarrard DF**. Upper tract Transitional Cell Carcinoma. In: Plantz SR ed., *Emedicine: Surgery*. www.emedicine.org , 2001.
3. Fu VX, Schwarze SR, Reznikoff CR and **Jarrard DF**. The establishment and characterization of transitional cell cancer *in vitro*. In: Freshney, RI and Pfagner, R. *The Culture Of Human Tumor Cells*. Wiley and Sons; 97-125, 2003.
4. **Jarrard DF**. Nerve-Sparing Radical Prostatectomy. In: Bruskewitz RC. *Atlas of the Prostate*, 2nd edition. Current Science Group; 135-147, 2003
5. Potretzke A, Downs T, and **Jarrard DF**. Upper tract Transitional Cell Carcinoma. In: Plantz SR ed., *Emedicine: Surgery*. www.emedicine.org , 2006 and 2012.
6. **Jarrard DF**, Potretzke AM, Downs T. Urothelial Tumors of the Renal Pelvis and Ureters. *Medscape Reference*. www.emedicine.medscape.com/article/452449-overview , 2014.
7. Kimberly A. Maciolek, E. Jason Abel, **David F. Jarrard**, Tracy M. Downs. Kaposi's Sarcoma of the Penis and Scrotum. In Pagliaro L. *Rare Genitourinary Tumors*. Springer International Publishing AG, Cham 2016
8. **Jarrard DF**, Damodaran S, Potretzke A, Downs T. Urothelial Tumors of the Renal Pelvis and Ureters in *Medscape Drugs & Diseases*. Sept-2016. (<http://reference.medscape.com/>)
9. **Jarrard D**, Damodaran S. Open Radical Retropubic Prostatectomy. *Medscape Drugs and Diseases*. July 2017. (<http://reference.medscape.com/>)

10. **Jarrard D.** 'Managing the Operating Room: A Urologists Guide to Enhancing Efficiency and Quality. In Nakada S and Patel S. Navigating Organized Urology: A Practical Guide. Springer International Publishing AG, Cham 2019
11. VanderGriend D, Zhao S, McKay R and **Jarrard D.** 'Molecular Genetics and Cancer Biology' in Campbell's Urology 14th ed., Elsevier Publishing 2024

Presentations (National/International)

1. **Jarrard DF**, Hansen NM, Rukstalis DB. Effect of epidermal growth factor on prostate cancer cell line PC3 growth and invasion. J Urol 147:485A. American Urological Association Annual Meeting, Washington, DC. May 1992.
2. Tomaszewski CS, **Jarrard DF**, Rukstalis DB. Protease and Protease inhibitor characteristics of four prostate cancer cell lines. J Urol 147:808A. American Urological Association Annual Meeting, Washington, DC. May 1992.
3. **Jarrard, DF.** High levels of de novo methylation at CpG islands are found in the human prostate. American Association of Cancer Research Meeting Annual Meeting. Palm Springs, CA. December 1994.
4. **Jarrard, DF.** Basic and Clinical Aspects of Prostate Cancer. American Association of Cancer Research Meeting Annual Meeting. Palm Springs, CA. December 1994.
5. **Jarrard DF**, Ewing CM, Morton RA, Bussemakers MB, Bova GS, and Isaacs WB. High levels of *de novo* methylation at CpG islands are found in the human prostate. J Urol 153:344A. American Urological Association Annual Meeting, Las Vegas, NV. April 1995.
6. Rutchik SD, **Jarrard DF**, Patai BL, and Tukstalis DB. Plasminogen activator inhibitor expression in the prostate. J Urol 153:380A. American Urological Association Annual Meeting, Las Vegas, NV. April 1995.
7. **Jarrard DF**, Ewing CM, Morton RA, Bussemakers MB, and Isaacs WB. Tissue-specific alteration in methylation at CpG Islands occurs frequently in the human prostate. J Urol 153:344. American Urological Association Annual Meeting. Las Vegas, NV. April 1995.
8. **Jarrard DF**, Bussemakers MJ, Bova GS, Isaacs WB. Regional loss of imprinting of the insulin-like growth factor II gene occurs in human prostate tissues. Cancer: The Interface between Basic and Applied Research, American Association of Cancer Research Meeting Annual Meeting. Baltimore, MD. November 1995.
9. **Jarrard DF**, Bova GS, Ewing CM, Pin SS, Nguyen SH, Baylin SB, Cairns P, Sidransky D, Herman JG, Isaacs WB. Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer. Society of Basic Urologic Research Fall Symposium Annual Meeting. Chapel Hill, NC. December 1995.
10. **Jarrard DF**, Graff JR, Bova GS, Robinson JC, Bussemakers M, Schalken J, Baylin SB, and Isaacs WB. E-cadherin and P-cadherin expression is silenced by DNA hypermethylation in prostate cancer. J Urol 155:602A. American Urological Association Annual Meeting. Orlando, FL. May 1996.
11. **Jarrard DF**, Bova GS, Ewing CM, Herman JG, Pin SS, Nguyen SH, Cairns P, Sidransky D, Baylin SB, and Isaacs WB. Deletional, mutational and methylation analyses of P16/CDKN2/MTS1 inactivation in primary and metastatic prostate cancer. J Urol 155:603A. American Urological Association Annual Meeting. Orlando, FL. May 1996.
12. Nguyen SH, **Jarrard DF**, and Isaacs WB. Treatment of prostate cancer cell lines with demethylating agents leads to alterations in tumor suppressor gene expression. J Urol 155:350A. American Urological Association Annual Meeting. Orlando, FL. May 1996.
13. Bova GS, Eisenberger M, Carducci M, Pin SS, **Jarrard DF**, Epstein JI, Isaacs JT, and Isaacs WB. "Molecular" autopsy study of lethal prostate cancer. J Urol 155:529A. American Urological Association Annual Meeting. Orlando, FL. May 1996.

14. **Jarrard DF**, Paul R, van Bokhoven A, Nguyen SH, Bova GS, Wheelock MJ, Johnson KR, Schalken J, Bussemakers M, Isaacs WB. P-Cadherin is a basal cell-specific epithelial marker that is not expressed in prostate cancer. North Central Section of the AUA Annual Meeting. Tempe, AZ. November 1996.
15. **Jarrard DF**, Ewing CM, Nguyen SH, Morton RA, Bussemakers MB, and Isaacs WB. Tissue-specific alterations in methylation at CpG-rich regions Occur frequently in the human prostate. American Association of Cancer Research Proceedings, Vol. 37, Washington, DC. April 1996.
16. **Jarrard DF**, Expression of DNA Methyltransferase in normal human prostate, prostate cancer and prostate cancer cell lines. American Association of Cancer Research Meeting Annual Meeting. March 1997.
17. Yang ES, David-Beabes GL, Veeraswamy GL, **Jarrard DF**, Brooks JD, Nelson WG. Expression of DNA Methyltransferase in normal human prostate, prostate cancer and prostate cancer cell lines. American Association of Cancer Research Proceedings, Vol. 38, San Diego, CA. March 1997.
18. **Jarrard DF**, Kinoshita H, Shi Y, Sandefur C, Hoff D, Meisner LF, Chang C, Herman JG, Isaacs WB, Nassif N. Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. American Association of Cancer Research Special Conference Annual Meeting. San Juan, Puerto Rico. December 1997.
19. Kinoshita H, Nassif N, Nelson WG, **Jarrard DF**. Cell cycle-associated expression of cytosine-methyltransferase (MeTase) in metastatic cancer and normal prostate epithelial cell lines. American Association of Cancer Research Proceedings, Vol. 39, New Orleans, LA. March 1998.
20. **Jarrard DF**, Yeager TR, Nassif N, Sandefur CE, Reznikoff CA. Loss of either P16/cdkn2 or RB is required for overcoming senescence in human prostate epithelial cells. J Urol 159(5):71. American Urological Association Annual Meeting. San Diego, CA. May 1998.
21. Nassif N, Sandefur CE, **Jarrard DF**. Identifications of DNA methylation markers in prostate tissues using a methylation-sensitive arbitrarily-primed PCR technique. J Urol 159(5):181. American Urological Association Annual Meeting. San Diego, CA. May 1998.
22. Yeager TR, Devries S, **Jarrard DF**, Kao CH, Nakada SY, Moon TD, Bruskewitz R, Stadler WM, Meisner LF, Gilchrist KW, Newton MA, Waldman FM, Reznikoff CA. Cellular senescence in human cancer pathogenesis. J Urol 159(5):286. American Urological Association Annual Meeting. San Diego, CA. May 1998.
23. Yeager TR, Devries S, **Jarrard DF**, Kao CH, Nakada SY, Moon TD, Bruskewitz R, Stadler WM, Meisner LF, Gilchrist KW, Newton MA, Waldman FM, Reznikoff CA. Identification of DNA methylation markers in prostate tissues using a methylation-sensitive arbitrarily- primed PCR technique American Urological Association Annual Meeting, San Diego, CA. May 1998.
24. **Jarrard DF**, Kinoshita H, Shi Y, Sandefur C, Hoff D, Meisner LF, Chang C, Herman JG, Isaacs WB, Nassif N. Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. American Association of Cancer Research Special Conference on New Approaches in the Prevention and Cure of Prostate Cancer Annual Meeting. Palm Springs, CA. December 1998.
25. **Jarrard DF**, Shi Y, Yeager TR, Nassif N, Meisner LB, Reznikoff CA. Alterations in the P16/retinoblastoma pathway is required for overcoming senescence in prostate epithelial cells. J Urol 161(4):63. American Urological Association Annual Meeting. Dallas, TX. May 1999.
26. **Jarrard DF**, Kinoshita H, Shi Y, Sandefur C, Hoff D, Meisner LF, Chang C, Herman JG, Isaacs WB, Nassif N. Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. American Urological Association Annual Meeting, Dallas, TX. May 1999.
27. **Jarrard DF**, Kinoshita H, Shi Y, Sandefur C, Hoff D, Meisner LF, Chang C, Herman JG, Isaacs WB, Nassif N. Methylation of the androgen receptor promoter CpG island is

- associated with loss of androgen receptor expression in prostate cancer cells. Gordon Research Conference at the Tilden School Annual Meeting. Tilden, NH. August 1999.
28. Kinoshita H, Shi Y, Sandefur C, Chang C, Choon A, Reznikoff CA, Bova GS, Friedel A, **Jarrard DF**. Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer. American Association of Cancer Research Proceedings, Vol. 41, April 1, 2000.
 29. Modder J, Fadden P, Seebree L, Yan Shi, Reznikoff CR, Friedel A, **Jarrard DF**. Tissue array analysis of human prostate cancer reveals alterations in the p16/pRb pathway occur frequently. J Urol 163(4):35. American Urological Association Annual Meeting. Atlanta, GA. April 2000.
 30. Kinoshita H, Shi Y, Sandefur C, and **Jarrard DF**. Histone deacetylation and DNA Methylation synergise to silence and AR expression in prostate cancer cells. J Urol 163(4):97. American Urological Association Annual Meeting. Atlanta, GA. April 2000.
 31. Modder J, Fadden P, Seebree LA, Shi Y, Reznikoff CA, Friedl A, **Jarrard DF**, Tissue array analysis of human prostate cancer reveals alterations in the p16/pRb pathway occur frequently. J Urol 163(4):152, American Urological Association Annual Meeting. Atlanta, GA. April 2000.
 32. **Jarrard DF**, p16/pRb are frequently inactivated in prostate cancer progression. Society of Basic Urologic Research Annual Meeting Annual Meeting. Fort Meyers, FL. November 2000.
 33. Schwarze SR, Shi Y, Fu VX, Watson PA, **Jarrard DF**, Role of cyclin-dependent kinase inhibitors in the growth arrest at senescence in human prostate epithelial and uroepithelial cells. Society of Basic Urologic Research Annual Meeting Annual Meeting. Fort Meyers, FL. November 2000.
 34. Schwarze SR, Shi Y, **Jarrard DF**. Role of cyclin-dependent kinase inhibitors in the onset of senescence in human prostate epithelial and urothelial cells. American Association of Cancer Research Proceedings, Vol. 42, March 12, 2001.
 35. Johnson DB, **Jarrard DF**. Preliminary experience with open laparotomy versus minimal preperitoneal laparotomy (MPL) for bladder cancer staging during radical cystectomy. J Urol 165(4):1253, American Urological Association Annual Meeting. . Anaheim, CA. May 2001.
 36. **Jarrard DF**, Loss Of IGF-II Imprinting Occurs During Senescence In Human Prostate Epithelial Cells. American Association of Cancer Research Annual Meeting. Palm Springs, CA. October 2001.
 37. **Jarrard DF**, Epigenetics and cancer. American Association of Cancer Research Annual Meeting. Palm Springs, CA. October 2001.
 38. **Jarrard DF**, Loss of IGF-II Imprinting Characterizes Epithelial Cell Senescence. American Federation of Aging Research Annual Meeting. New York, NY. April 2002.
 39. Han S, Lee D, Demarzo A, Friedl A, **Jarrard DF**. P16 Upregulation Characterizes Proliferative Inflammatory Atrophy of the Prostate. J Urol 167(4): 137, American Urological Association Annual Meeting. . Orlando, FL. May 2002.
 40. Fu VX, Schwarze SR, **Jarrard DF**. Loss of IGF-II Imprinting Occurs During Senescence in Human Prostate Epithelial Cells. J Urol 167(4): 135, American Urological Association Annual Meeting. . Orlando, FL. May 2002.
 41. Schwarze SR, DePrimo SE, Grabert LM, Fu V, Brooks JD, and **Jarrard DF**. Novel pathways Associated with Bypassing Cellular Senescence in Human Prostate Epithelial Cells. J Urol 167(4): 139, American Urological Association Annual Meeting. . Orlando, FL. May 2002
 42. **Jarrard DF**, Induction of Senescence in Prostate Cancer. Annual CaPCURE Foundation Meeting. Washington, DC (poster). September 2002.
 43. **Jarrard DF**, P16 Upregulation Characterizes Proliferative Inflammatory Atrophy of the Prostate. North Central Section of the AUA. Chicago, IL. September 2002.
 44. Jones SB, Chon CH, Marotte JB, **Jarrard DF**, Brown PO, and Brooks JD. Gene expression profiles of testicular cancer. American Association of Cancer Research Proceedings, Vol. 44, July 2003.

45. **Jarrard DF**, Grabert LM, Fu VX, and Schwarze SR. The induction of cellular senescence as novel therapy for prostate cancer. American Association of Cancer Research proceedings, Vol. 44, July 2003.
46. **Jarrard DF**, Induction of senescence for advanced prostate cancer. Annual CaPCURE Foundation Meeting. New York, NY. November 2003.
47. Schwarze SR, Isaacs WB, Oberley T, and **Jarrard DF**. CXCL 14 expression is elevated in prostate cancer and may promote tumor progression through inflammation and endothelial cell recruitment. J Urol 171(4): 156, 2004. American Urological Association Annual Meeting. San Francisco, CA. May 2004.
48. **Jarrard DF**, Grabert LM, Fu VX, and Schwarze SR. The induction of cellular senescence as novel therapy for prostate cancer. J Urol 171(4): 382, 2004. American Urological Association Annual Meeting. San Francisco, CA. May 2004.
49. **Jarrard DF**, Grabert LM, Fu VX, and Schwarze SR. The induction of cellular senescence as novel therapy for prostate cancer. J Urol 171(4): 382, American Urological Association Annual Meeting. . San Francisco, CA. May 2004.
50. Fu VX, Schwarze SR, Kenowski ML, Leblanc S, Svaren J, **Jarrard DF**. A loss of insulin-like growth factor-2 imprinting is modulated by CCCTC-binding factor down-regulation at senescence in human epithelial cells. Imprinting and Disease International Meeting. Montpellier, France. September 2004.
51. **Jarrard DF**, High dose zinc increases GU hospitalizations. North Central Section of the AUA. Palm Beach, FL. October 2004.
52. **Jarrard DF**, Senescence as therapy for prostate cancer. Prostate Foundation Meeting. Lake Tahoe, CA. October 2004.
53. Kidel AS, Picus J, Cookson MS, Roth B, **Jarrard DF**, Wilding GW, Klein EA et al., Adjuvant weekly docetaxel for high-risk prostate cancer patients after radical prostatectomy. J Urol (4):222, American Urological Association Annual Meeting. San Antonio, TX. May 2005.
54. Fu VX, Kenowski ML, Schwarze SR, LeBlanc S, Svaren J, **Jarrard DF**. A loss of insulin-like growth factor-2(IGF2) imprinting is modulated by CTCF downregulation at senescence in human epithelial cells. J Urol(4): 68, American Urological Association Annual Meeting. San Antonio, TX. May 2005.
55. Fu VX, Schwarze SR, Kenowski ML, Leblanc S, Svaren J, **Jarrard DF**, A loss of insulin-like growth factor-2 imprinting is modulated by CCCTC-binding factor down-regulation at senescence in human epithelial cells. Epigenetics and Environment Meeting. Durham, NC. October 2005.
56. **Jarrard DF**, Alteration of IGF2 imprinting in the prostate by methyl-deficient diets. Epigenetics and Environment Meeting, Durham, NC. October 2005.
57. Wilkin M, Horowitz G, Hartenbach E, Bruskewitz R, **Jarrard DF**. Long-term risks associated with Indiana pouch urinary diversion in female patients with and without prior pelvic radiation. Urologic Oncology 23:2005. 12-15. Bethesda, MD. December 2005.
58. Saleem M, Adhmai V, Zong W, Longley J, Lin C, Dickson R, Reagan-Shaw S, **Jarrard DF**, and Muchtar H. A Novel Biomarker for Staging Human Prostate Adenocarcinoma: Overexpression of Matrilysin with Concomitant Loss of its Inhibitor, Hepatocyte Growth Factor Activator Inhibitor-1. AACR, April 2006.
59. **Jarrard DF**, Drug induced senescence induces proliferation in vitro but not in vivo. American Association of Cancer Research Meeting. Washington, DC. April 2006.
60. Doboey JA, Fu VX, Roberts JL, Desotelle JA, Almassi N, Weindruch R, and **Jarrard DF**. Methyl-deficient diet leads to an increase in Insulin-like growth factor-2 expression in the prostate. J Urol(4): 512, American Urological Association Annual Meeting. . Atlanta, GA. May 2006.

61. Ewald JA, Desotelle JA, Almassi N, and **Jarrard DF**. Biologic Effect of Senescent Prostate Cancer Cells *In Vitro* and *In Vivo*. J Urol(4): 84, American Urological Association Annual Meeting. . Atlanta, GA. May 2006.
62. Kibel AS, Kattan MW, Picus J, Dreicer R, Klein EA, Wilding GW, **Jarrard DF**, Roth B, et al., Adjuvant Weekly Docetaxol for High-Risk Prostate Cancer Patients after Radical Prostatectomy. J Urol(4):512, American Urological Association Annual Meeting.. Atlanta, GA. May 2006.
63. Johnson A, Munoz A, Gottlieb J, **Jarrard DF**. High-dose Zinc Increases Hospital Admissions Due to Genitourinary Complications. J Urol. 144(4): 21, American Urological Association Annual Meeting. Anaheim, CA. May 2007.
64. Ewald JA, Laurila T, Almassi, Dosetelle JA, **Jarrard DF**. A Novel High Throughput Screen Identifies Potent Senescence-Inducing Activity of Diaziquone (AZQ) in Prostate Cancer Cells. J Urol, American Urological Association Annual Meeting. . Orlando, FL. May 2008 (Best Poster Award Winner).
65. Fu VX, Dobosy J, Dosetelle JA, Almassi N, Ewald JA, Srinivasan R, Svaren J, Weindruch RH, **Jarrard DF**. Aging Related Loss of Insulin-Like Growth Factor-2 (Igf2) Imprinting in the Prostate. American Urological Association Annual Meeting. . Orlando, FL. May 2008.
66. Kibel A, Eisenberger M, Picus J, Dreicer R, Klein E, Roth B, Cookson M, Wilding G, **Jarrard DF**, Salavaggione L, Watson M. Gene Expression Profiling for the Prediction of Therapeutic Response to Adjuvant Docetaxel for High Risk Localized Prostate Carcinoma. American Urological Association Annual Meeting. . Orlando, FL. May 2008.
67. Laurila T, Ewald JA, Church DR, Almassi N, **Jarrard DF**. Androgen Ablation Induces Senescence Characteristics In Vivo and In Vitro. J Urol, American Urological Association Annual Meeting. . Orlando, FL. May 2008.
68. Fu VX, Dobosy JR, Desotelle JA, Almassi N, Ewald JA, Srinivasan R, Berres M, Svaren J, Weindruch R, **Jarrard DF**. Aging and cancer-related loss of insulin-like growth factor 2 imprinting in the mouse and human prostate. Cancer Epigenetics AACR Meeting, Boston, MA May 2008.
69. Fu VX, Dobosy JR, Desotelle JA, Almassi N, Ewald JA, Srinivasan R, Berres M, Svaren J, Weindruch R, **Jarrard DF**. Aging and cancer-related loss of insulin-like growth factor 2 imprinting in the mouse and human prostate. American Association of Cancer Research Annual Meeting- Prostate Cancer Section. San Diego, CA. January 2009.
70. Ewald JA, Almassi N, Desotelle JA, Laurila T, Hoffman FM, **Jarrard DF**. Anti-Proliferative Senescence-Induced Effects of Diaziquone (AZQ) on Prostate Cancer *In Vitro* and *In Vivo*. American Association of Cancer Research Annual Meeting- Advances in Prostate Cancer Research. San Diego, CA. January 2009.
71. Ewald JA, Desotelle JA, Hoffman FM, **Jarrard DF**. Senescence as Cytostatic Therapy: Drug-Induced Senescence in Prostate Cancer Cells Requires SKP2-Regulated P27KIP1 Expression. J Urol American Urological Association Annual Meeting. San Francisco, CA. May 2010.
72. Yang B, Kueck J, Bhusari S, Huang W, **Jarrard DF**. Defining the Field Defect Associated With Prostate Cancer Development Using Unbiased Methylation Profiling. American Urological Association Annual Meeting. San Francisco, CA. May 2010.
73. King AC, Livermore A, Laurila TA, Huang W, **Jarrard DF**. Impact of immediate TRUS rebiopsy in a patient cohort considering active surveillance for favorable risk prostate cancer. Society of Urologic Oncology Annual Meeting. Bethesda, MD. December 2010.
74. Babian K, Cross D, Ritter M, Cetnar J and **Jarrard DF**. End of Life Complications in Men Dying From Prostate Cancer Treated With And Without Radical Prostatectomy Using A Population-Based Approach. 11th Annual meeting of the Society of Urologic Oncology. Bethesda, MD. December 2010.
75. Ewald JA, Desotelle JA, Hoffman FM, **Jarrard DF**. Senescence as Cytostatic Therapy: Drug-Induced Senescence in Prostate Cancer. IMPACT meeting, Orlando, FL March 2011

76. Bhusari S, Yang B, Huang W, **Jarrard DF**. Insulin-Like Growth Factor-2 (IGF2) Loss of Imprinting Marks A Field Defect within Human Prostates Containing Cancer. American Urological Association Paper Presentation. Washington, DC. May 2011
77. Ewald J, Desotelle J, Church D, Laurila T, **Jarrard DF**. Androgen Deprivation Induces a Delayed Senescent Phenotype in Prostate Cancer. American Urological Association Paper Presentation. Washington, DC. May 2011
78. Yang B, Kueck J, Bhusari S, Huang W, **Jarrard DF**. Defining the Field Defect Associated With Prostate Cancer Development Using Unbiased Methylation Profiling. European Society for Urological Research. Innsbruck, Austria. September 2011.
79. Yang B, Kueck J, Bhusari S, Huang W, **Jarrard DF**. Defining the Field Defect Associated With Prostate Cancer Development Using Unbiased Methylation Profiling. Society for Basic Urologic Research, Las Vegas, NV. November 2011.
80. McGetrick JJ, Downs TM, Sado M, **Jarrard DF**, Abel EJ, Symptomatic Pulmonary Embolism in Major Urologic Cancer Surgery. American Urological Association Paper Presentation. Atlanta, GA. May 2012
81. Truong M, Babaian K, Cetnar J, Cross D, Shi F, Ritter M, **Jarrard DF**. Predictors of Urological Procedures in Men Dying from Prostate Cancer Using a Population-Based Approach. American Urological Association Annual Meeting. Atlanta, GA. May 2012. (Best Poster Award Winner)
82. Truong M, Yang B, Kobayashi Y, Brooks J, **Jarrard DF**. Even-Skipped Homeobox 1 (Evx1) Is Frequently Hypermethylated in Prostate Cancer and Predicts PSA Recurrence. American Urological Association Annual Meeting. Atlanta, GA. May 2012
83. Downs TD, Potrezke A, Hillman L, Abel EJ and **Jarrard DF**. Neutrophil Lymphocyte Ratio (Nlr) is Predictive of Upstaging at the Time of Radical Cystectomy for Patients with Urothelial Carcinoma of the Bladder. Society for Urologic Oncology, Washington, DC. December 2012.
84. **Jarrard DF**, Lin D, Nelson J, Dhir R, Huang H, Livermore A, Yang B and Truong M. Employing the Epigenetic Field Effect to Detect Prostate Cancer in Biopsy-Negative Patients. Society for Urologic Oncology, Washington, DC. December 2012.
85. Truong M, Slezak J, Huang W, **Jarrard D**. HP1Y is Elevated in Prostate Cancer and is Superior to Gleason Score as a Predictor of Biochemical Recurrence After Radical Prostatectomy. American Urological Association Annual Meeting. San Diego, CA. May 2013
86. Shiau J, Truong M, Slezak J, Abel EJ, Downs T, **Jarrard D**. Novel Approach to Risk Stratification in Patients Considering Active Surveillance. American Urological Association Annual Meeting. San Diego, CA. May 2013.
87. Truong M, Iremashvili V, Lin CP, Slezak J, Sado M, Razmaria A, Soloway M, Eggner S, Abel EJ, Downs T, **Jarrard D**. Development and Multi-Institutional Validation of A biopsy-Integrated Algorithm for Determining Gleason 6 Upgrading Risk. American Urological Association Annual Meeting. . San Diego, CA. May 2013.
88. Downs T, Abel EJ, Powell A, Levenson G, **Jarrard D**, Mezrich J. Bladder Cancer Incidence and Survival in Organ Transplant Recipients: The University of Wisconsin Experience. American Urological Association Annual Meeting. San Diego, CA. May 2013.
89. Truong M, Yang B, Livermore A, Wagner J, Weeratunga P, Huang W, Dhir R, Nelson J, Lin D, **Jarrard D**. Employing the Epigenetic Field Effect to Detect Prostate Cancer in Biospy-Negative Patients. American Urological Association (Oral Presentation). San Diego, CA. May 2013.
90. Wagner J, Truong M, Yang B, Guenther C, Huang W, and **Jarrard DF**. Increased lysosomal B-galactosidase expression is a senescence marker and identifies indolent prostate cancer. Prostate Cancer Foundation 20th Annual meeting. Washington DC. Oct 2013.
91. Abel EJ, Linder BJ, Downs TD, Bauman TM, Thompson RH, Trapa P, Devon ON, Tarrell RF, Frank I, Tollefson MK, **Jarrard DF**, Boorjian SA. Intraoperative Blood Transfusion During Radical Cystectomy Increased The Risk Of Death From Bladder Cancer Compared To Postoperative Transfusion. SUO meeting, Washington DC. December 2013

92. Slawin K, Ellis W, Tenke P, Joniau S, Alekseev BY, Buzogány I, Mishugin S, Klein EA, Karnes RJ, Scherr D, Yuh BE, **Jarrard DF**, Trabulsi EJ, Stolz J, Babich J, Youssefian H, Stambler N, Armor T, Israel RJ. A phase II study of 99mtc-trofolastat (MIP-1404) SPECT/CT to identify and localized prostate cancer in high-risk patients undergoing radical prostatectomy (RP) and extended pelvic lymph node dissection (EPLND) compared to histopathology: An interim analysis. Genitourinary Cancers Symposium. January 2014.
93. Abel EJ, Linder BJ, Downs TD, Bauman TM, Thompson RH, Trapa P, Devon ON, Tarrell RF, Frank I, Tollefson MK, **Jarrard DF**, Boorjian SA. Intraoperative Blood Transfusion During Radical Cystectomy Increased The Risk Of Death From Bladder Cancer Compared To Postoperative Transfusion. American Urological Association Annual Meeting (Moderated Poster Session). Orlando, FL. May 2014.
94. Damaschke N, Huang W, Lin CP, Lee JH, **Jarrard DF**. Disruption of Chd8-Ctcf Chromatin Complex In Prostate Cancer Alters Dna Methylation Patterns. American Urological Association Annual Meeting (Moderated Poster Session). Orlando, FL. May 2014.
95. Allen H, Abel EJ, Shapiro DD, Shi F, Potretzke A, **Jarrard DF**, Ziemiewicz TJ, Downs TM. Core muscle size predicts 6-month mortality in patients undergoing radical cystectomy. American Urological Association Annual Meeting (Moderated Poster Session). Orlando, FL. May 2014.
96. Bauman TM, Marguils V, Wood CG, Christensen WP, Golla V, Youssef RF, Krabbe LM, **Jarrard DF**, Downs TM, Abel EJ. Curative surgery in RCC with thrombus: a comprehensive risk model from a modern multicenter analysis. American Urological Association Annual Meeting (Moderated Poster Session). Orlando, FL. May 2014.
97. Omernick KE, Abel EJ, Tevis SE, Shapiro DD, **Jarrard DF**, Kennedy GD, Downs TM. Identifying patients at high-risk for readmission after radical cystectomy using the national surgical quality improvement program database. American Urological Association Annual Meeting (Moderated Poster Session). Orlando, FL. May 2014.
98. Sweeney C, Chen YH, Carducci MA, Liu G, **Jarrard DF**, Eisenberger MA, Wong YN, Hahn NM, Koshli M, Vogelzang NJ, Cooney MM, Dreicer R, Picus J, Shevrin DH, Hussain M, Garcia JA, DiPaola RS. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. American Society of Clinical Oncology Annual Meeting (Moderated Poster Session). Chicago, IL. May 2014.
99. Sweeney C, Chen YH, Carducci MA, Liu G, **Jarrard DF**, Eisenberger MA, Wong YN, Hahn NM, M Kohli M, Vogelzang N, Cooney MM, Dreicer R, Picus J, Shevrin DH, Hussain M, Garcia JA, Dipaola RS. Chemohormonal therapy versus hormonal therapy for hormone naïve high volume newly metastatic prostate cancer (PrCa): ECOG led phase III randomized trial. European Society Medical Oncology 2014 Scientific Committee (Proffered Paper Presentation). Madrid, Spain. September 2014.
100. Wagner J, Damaschke N, Truong M, Yang B, Guenther C, Huang W, and **Jarrard DF**. Increased lysosomal B-galactosidase (GLB1) expression is a senescence marker and identifies indolent prostate cancer. Prostate Cancer Foundation Meeting, San Diego, CA. October 2014.
101. Damaschke NA, Yang B, Blute ML Jr, Lin CP, Huang W, **Jarrard DF**. Frequent Disruption of Chromodomain Helicase DNA-Binding Protein 8 (CHD8) and Functionally Associated Chromatin Regulators in Prostate Cancer. SBUR meeting Dallas, TX. November 2014.
102. Blute, Jr ML, Rushmer TJ, Shi F, Fuller B, Abel EJ, **Jarrard DF** Downs TM. Renin-angiotensin Inhibitors Decrease Recurrence after TURBT in Non-muscle Invasive Bladder Cancer. American Urological Association Annual Meeting (Moderated Poster Session). New Orleans, LA. May 2015.
103. Blute, Jr ML, Rushmer TJ, Shi F, Fuller B, Abel EJ, **Jarrard DF** Downs TM. Moderate Chronic Kidney Disease (eGFR <60ml/min) Predicts Recurrence and Progression in Bladder Cancer Patients Treated with Transurethral Resection. American Urological Association Annual Meeting (Moderated Poster Session). New Orleans, LA. May 2015.

104. Blute, Jr ML, Yang B, Damaschke N, Lamming D, Hoffman FM, **Jarrard DF**. Synthetic lethal metabolic targeting of cellular senescence in prostate cancer with metformin. American Urological Association Annual Meeting (Moderated Poster Session). New Orleans, LA. May 2015.
105. Heckman JE, Ziemlewicz T, Best S, Lubner M, Hinshaw L, **Jarrard DF**, Downs TM, Huang W, Lee FT, Nakada SY, Abel EJ. Multi-quadrant Biospy Technique Decrease Sampling Error in Large Heterogeneous Renal Tumors. American Urological Association Annual Meeting (Moderated Poster Session). New Orleans, LA. May 2015.
106. Blute, Jr ML, Wagner J, Damaschke N, Yang B, Gleave M, Fazli L, Huang Wei, **Jarrard DF**. Neoadjuvant Androgen Deprivation Therapy Induces Senescence in Radical Prostatectomy Specimens. American Urological Association Annual Meeting (Moderated Poster Session). New Orleans, LA. May 2015.
107. Patrick-Miller LJ, Chen YH, Carducci MA, Cella D, DiPaola RS, Gartrell BA, **Jarrard DF**, Liu G, Morgans AK, Wong YN, Sweeney C. Quality of life (QOL) analysis from E3805, chemohormonal androgen ablation randomized trial (CHAARTED) in prostate cancer (PrCa). American Society of Clinical Oncology- Genitourinary Cancers Symposium. San Francisco, CA. January 2016.
108. Yang B, McCormick J, Damaschke N, Montgomery A, Levenson G, Huang W, Lin DW, **Jarrard DF**. Employing the epigenetic field effect to detect prostate cancer in biopsy-negative patients. Minisymposium: Clinical Qualification of Impactful NGS-based Biomarkers. American Association of Clinical Research Annual Meeting. New Orleans, LA. April 2016
109. Damaschke NA, Yang B, Montgomery A, Svaren J, Roopra A, Luo J, Keles S, **Jarrard DF**. CTCF acts as a master regulator to direct epigenetic events important for tumor development and progression. Association of Clinical Research Annual Meeting. (Moderated Poster Session) New Orleans, LA. April 2016.
110. Blute ML, Kucherov V, Shapiro DD, Rushmer TJ, Shi F, Fuller B, Richards KA, Abel EJ, **Jarrard DF**, Messing EM, Downs TM. Moderate Chronic Kidney Disease (eGFR<60 ml/min) predicts recurrence and progression in bladder cancer patients treated with transurethral resection. American Urological Association Annual Meeting. (Moderated Poster Session) San Diego, CA. May 2016.
111. Grimes MD, Blute ML, Mann MA, Downs TM, Shi F, **Jarrard DF**, Best SL, Richards KA, Nakada SY, Able EJ. A critical analysis of postoperative morbidity in morbidly obese patients following renal cancer surgery. American Urological Association Annual Meeting. San Diego, CA. May 2016.
112. McCormick JR, Blute ML, Yang B, Damaschke N, **Jarrard DF**. Synthetic Lethal Metabolic Targeting of Cellular Senescence in Prostate Cancer with the Repurposed Drug Metformin. American Urological Association Annual Meeting. San Diego, CA. May 2016.
113. **Jarrard DF**, Konety BR, Slaton J, Huang W, Downs TM, Kolesar J, Kim KM, Havighurst, T, House MG, Parnes HL, Bailey HH. Phase IIa, randomized placebo-controlled trial of single high dose cholecalciferol (vitamin D₃) and daily Genistein (G-2535) versus placebo in men with early stage prostate cancer undergoing prostatectomy. American Urological Association Annual Meeting. San Diego, CA. May 2016.
114. Lee J-H, Yang BH, Lindahl, A, Damaschke NH, Boersma MD, Huang WH, Corey E, **Jarrard DF***, Denu JM* (*Co-senior authors). Identifying dysregulated epigenetic enzyme activity in castrate-resistant prostate cancer development. Prostate Cancer Foundation meeting. Carlsbad, CA. September 2016.
115. Sierra P, Wang J, Richards KA, Abel EJ, Downs TM, Shi FF, **Jarrard DF**. Bilateral Prostate Cancer Found On Prostate Biopsy in Patients Considering Active Surveillance: Detection Not Progression. Society of Urologic Oncology Annual Meeting. San Antonio, TX. December 2016.

116. **Jarrard DF**, Konety B, Huang W, Downs TM, Kolesar J, Kim KM, Havighurst T, Slaton J, House M, Parnes H and Bailey H. Phase IIA, Randomized Placebo-Controlled Trial Of Single High Dose Cholecalciferol (Vitamin D3) And Daily Genistein (G-2535) Versus Placebo In Men Undergoing Prostatectomy. Society of Urologic Oncology Annual Meeting. San Antonio, TX. December 2016.
117. Harshman LC, Chen YH, Liu G, Carducci MA, **Jarrard DF**, Dreicer R, Hahn NM, Garcia JA, Hussain M, Shevrin DH, Eisenberger MA, Kohli M, Wong YN, Cooney MM, Vogelzang NJ, Picus J, DiPaola RS, Sweeney C. Lower PSA at 7 months is prognostic for improved overall survival (OS) in metastatic hormone sensitive prostate cancer (mHSPC) treated with ADT with and without docetaxel (D). American Society of Clinical Oncology 2017 Genitourinary Cancers Symposium. Orlando, FL. February 2017.
118. Gravis G, Boher JM, Chen TH, Liu G, Fizazi K, Carducci MA, Oudard S, Joly F, **Jarrard DF**, Soulie M, Eisenberger MA, Habibian M, Dreicer R, Garcia JA, Hussain M, Kohli M, Vogelzang NJ, Picus J, DiPaola RS, Sweeney C. Burden of metastatic hormone-sensitive prostate cancer to identify men more likely to benefit from early docetaxel. American Society of Clinical Oncology 2017 Genitourinary Cancers Symposium. Orlando, FL. February 2017.
119. **Jarrard DF**, Chen YH, Carducci MA, Eisenberger MA, Wong YN, Hahn NM, Kohli Manish, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin DH, Hussain M, Garcia JA, DiPaola RS, Sweeney C. Impact of metformin on prostate cancer (PC) outcomes in the E3805 CHAARTED trial. American Society of Clinical Oncology 2017 Genitourinary Cancers Symposium. Orlando, FL. February 2017.
120. **Jarrard DF**, Lee JH, Boersma M, Yang B, Damaschke NA, Corey E, Denu JM. A personalized medicine approach to identifying dysregulated epigenetic enzymes in the development of castrate-resistant prostate cancer. American Society of Clinical Oncology 2017 Genitourinary Cancers Symposium. Orlando, FL. February 2017.
121. Yang B, McCormick J, Schultz A, Leverson G, Sonn G, Magi-Galluzi C, Klein EA, Fumo M, **Jarrard DF**. Clinical validation of an epigenetic field of susceptibility to detect significant prostate cancer from 2 non-tumor biopsies. American Association for Cancer Research Annual Meeting. Washington, DC. April 2017.
122. Lee J, Boersma M, Yang B, Damaschke N, Corey E, Denu J, Jarrard DF. A personalized medicine approach to identifying dysregulated epigenetic enzyme activity in the development of castrate-resistant prostate cancer. American Association for Cancer Research Annual Meeting. Washington, DC. April 2017.
123. **Jarrard DF**, Chen YH, Carducci MA, Eisenberger MA, Wong YN, Hahn NM, Kohli Manish, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin DH, Hussain M, Garcia JA, DiPaola RS, Sweeney C. Impact of metformin on prostate cancer (PC) outcomes in the E3805 CHAARTED trial. American Urological Association Annual Meeting. Boston, MA. May 2017.
124. Richards K, Liou J, Cryns V, Downs TM, Abel EJ, **Jarrard DF**. Metformin Use Is Associated with Improved Survival in Patients with Advanced Prostate Cancer on Androgen Deprivation Therapy. Prostate Cancer Foundation Meeting, Washington DC, Oct 2017.
125. Damodaran S, Mankowski Gettle L, Kelcz F, Allen GO, Richards KY, Abel EJ, Downs TB, **Jarrard DF**. MR imaging Of Prostate Cancer Shows Reduced Enhancement Kinetic Curves In Men On 5-alpha Reductase Inhibitors With Implications For Cancer Detection. American Urological Association Annual Meeting. San Francisco, CA. May 2018.
126. Bui A, Shapiro DD, Best SL, Wells SA, Mankowski Gettle L, Ziemlewicz TJ, Lubner MG, Hinshaw JL, Lee FT Jr, **Jarrard DF**, Richards KA, Downs TM, Nakada SY, Abel EJ. Shared decision making for treatment of small renal masses; a survey of patient's opinions before and after initial counseling. American Urological Association Annual Meeting. San Francisco, CA. May 2018.

127. Shapiro DD, Best SL, Wells SA, Ziemlewicz TJ, Lubner MG, Hinshaw JL, Lee FT Jr, **Jarrard DF**, Downs TM, Richards KA, Allen GO, Nakada SY, Abel EJ. Comparative analysis of perioperative outcomes for patients with 4-7cm RCC treated with either microwave ablation, partial nephrectomy or radical nephrectomy. American Urological Association Annual Meeting. San Francisco, CA. May 2018.
128. Cesnik AJ, Truong AV, Etheridge T, Yang B, Spiniello M, Steinbrink MI, Shortreed MR, Frey BL, Allen GO, **Jarrard DF**, Smith LM. Discovery and Validation of Novel Long Noncoding RNAs that Differentiate Aggressive and Indolent Prostate Cancer. American Urological Association Annual Meeting. San Francisco, CA. May 2018.
129. Posielski N, Anderson-Carter I, Liou J, Abel EJ, Downs TM, **Jarrard DF**, Richards KA. Use of statins in combination with androgen deprivation therapy in patients with advanced prostate cancer: impact on oncological outcomes. American Urological Association Annual Meeting. San Francisco, CA. May 2018.
130. Truong A, Roberge G, Liou J, Abel EJ, Downs TM, **Jarrard DF**, Richards KA. The impact of metformin use on oncologic outcomes in prostate cancer patients receiving docetaxel chemotherapy. American Urological Association Annual Meeting. San Francisco, CA. May 2018.
131. Khemees T, Liou J, Abel EJ, Downs TM, Borza T, **Jarrard DF**, Richards KA. Understanding the Role of Statin Use on Advanced Prostate Cancer Outcomes: Does the Statin Type Cumulative Dose or Duration Impact Survival? North Central Section of the American Urological Association Annual Meeting, Chicago, IL. September 2019.
132. Viswanathan A, Posielski N, Damodaron S, **Jarrard D**. Central Lesion Location Underlies the Learning Curve Associated With Targeted MRI/ Ultrasound Fusion Prostate Biopsies. North Central Section of the American Urological Association Annual Meeting, Chicago, IL. September 2019.
133. Khemees T, Yang B, Schultz A, Levenson G, Etheridge T, Sonn G, Magi-Galluzzi C, Klein EA, Fumo M, **Jarrard DF**. Epigenetic Methylation Differences are Greater Between Tumor-Associated Benign Prostate Tissues: The Field Effect Hypothesis. North Central Section of the American Urological Association Annual Meeting, Chicago, IL. September 2019.
134. Dreyfuss L, Wells S, Posielski N, Best S, Hedican S, Ziemiewicz T, Lubner M, Hinshaw JL, Lee F, Allen G, **Jarrard D**, Nakada S, Abel EJ. Risk Factors for Recurrence Following Ablation for Clinical T1 Renal Cell Carcinoma (RCC.) North Central Section of the American Urological Association Annual Meeting, Chicago, IL. September 2019.
135. Posielski N, Miller B, Abel EJ, Borza T, Allen G, Schumacher J, **Jarrard D**, Downs T, Richards, K. Trends in Utilization of Robotic and Open Approach to Radical Cystectomy: A Population-Based Study, 2002-2014. North Central Section of the American Urological Association Annual Meeting, Chicago, IL. September 2019.

Invited Presentations/Visiting Professorships

Local

1. March 19, 1997, "Hereditary prostate cancer and changing trends in prostate cancer diagnosis", Invited speaker, Beloit Hospital, Beloit, WI.
2. May, 14, 1997, "Tumor markers in genitourinary malignancies", Invited speaker, Annual Meeting of Dade International, Green Lake, WI.
3. August 7, 1997, "New concepts in prostate cancer diagnosis and screening", Invited speaker, St. Vincent Hospital, Green Bay, WI.

4. November 7, 1997, "Tumor markers in genitourinary malignancies", Invited speaker, Pathology Conference in the Department of Pathology and Laboratory Medicine, University of Wisconsin Hospital and Clinics, Madison, WI.
5. November 9, 1997, "Prostate cancer update", Invited speaker, CME Oncology Update, Freeport Hospital, Freeport, IL.
6. May 1, 1998, "New perspectives in prostate cancer Diagnosis", Invited speaker, Intern Physician Conference, University of Wisconsin Hospital, Madison, WI
7. May 16, 1998, "New perspectives on bladder cancer", Moderator. Wisconsin Urologic Association Meeting, Kohler, WI.
8. September 26, 1998, "Diseases of the prostate", Invited speaker, Wisconsin Board Review Course in Geriatric Medicine, Medical College of Wisconsin, Lake DeLevan, WI.
9. October 7, 1998, "Prostate cancer", Invited speaker, Man to Man Society, Madison, WI.
10. October 21, 1998, "Methylation alterations in prostate cancer" Invited speaker, UW Comprehensive Cancer Center Grand Rounds, University of Wisconsin Hospital, Madison, WI
11. April 26, 1999, "Methylation of the Androgen Receptor in human prostate cancer", Invited speaker, Genetics, McArdle Cancer Center, University of Wisconsin, Madison, WI
12. May 22, 1999, "New approaches to the treatment of recurrent prostate cancer", Invited speaker, Wisconsin Urologic Association Meeting, Kohler, WI. (moderator of prostate cancer section)
13. May 26, 1999, "Prostate cancer", Invited speaker, Kiwanis Club, Appleton, WI.
14. September 19, 1999. "Senescence inhibits prostate cancer: the benefit of growing old", Invited speaker, Department of Surgery Research meetings, Inntowner, Madison, WI.
15. May 21, 2000, "Open laparotomy versus minimal preperitoneal laparotomy (MPL) for bladder cancer staging during radical cystectomy", Invited speaker, Wisconsin Urologic Association Meeting, Kohler, WI.
16. May 21, 2000, Genitourinary Cancer session, Moderator, Wisconsin Urologic Association Meeting, Kohler, WI.
17. June 2, 2000, "Overcoming senescence in prostate cancer", Invited speaker, Cancer Genetics, McArdle Cancer Center, University of Wisconsin, Madison, WI
18. June 23, 2000, "Surgical management of bladder and prostate cancer", Invited speaker, Radiotherapy Grand Rounds, University of Wisconsin Hospital and Clinics, Madison, WI.
19. November 3, 2000, "Overcoming senescence in prostate cancer progression", Invited Speaker Society of Clinical Surgery, Madison, WI.
20. November 15-16, 2000. Prostate cancer screening. Invited speaker, WPTV TV3, Madison, WI.
21. December 6, 2000, "PSA in prostate cancer", Invited speaker, Man to Man Society, Madison, WI.
22. January 31, 2001, Three-part series on prostate cancer diagnosis and treatment. Moderated all 3 sessions. TV27, Madison, WI.
23. February 21, 2001, "Overcoming senescence in prostate cancer and surgical advances in radical prostatectomy", Invited speaker, Dept. of Surgery Grand Rounds, University of Wisconsin Hospital and Clinics, Madison, WI
24. April 19, 2001, "Alterations in genomic imprinting in epithelial cell senescence and prostate cancer", Invited speaker, Cancer Genetics, McArdle Cancer Center, University of Wisconsin, Madison, WI.
25. May 2, 2001, "Advances in prostate cancer research", Invited speaker, Man to Man Society, Madison, WI.
26. June 11, 2001, "Radical prostatectomy", Invited speaker, Radiotherapy Grand Rounds, University of Wisconsin Hospital and Clinics, Madison, WI.

27. June 27, 2001, "Overcoming senescence in prostate cancer progression", Invited speaker, UW Cancer Center Grand Rounds, University of Wisconsin Hospital and Clinics, Madison, WI.
28. August 22, 2001, "Controversies in prostate cancer treatment", Invited speaker, St. Vincent Hospital Grand Rounds, Oshkosh, WI.
29. September 12, 2001, "Selenium and Vitamin E chemoprevention" Invited speaker, UW West Clinic, Madison WI.
30. November 10, 2001, Moderator and meeting organizer of "New approaches in the management of prostate cancer". Speaker: "New strategies for nerve-sparing radical prostatectomy". The First Annual Uehling lectureship. Madison, WI.
31. February, 7, 2002, "Controversies in prostate cancer", Invited speaker, Mercy Health System, Janesville, WI.
32. February 15, 2002, "Screening for prostate cancer", Invited speaker, UW Internal Medicine Grand Rounds, University of Wisconsin Hospital and Clinics, Madison, WI.
33. February 5, 2002, "Bypassing Senescence as therapy in prostate cancer", Invited speaker, UW Cancer Center Grand Rounds, Madison, WI.
34. May 11, 2002, Moderator for Urologic Oncology session, Wisconsin Urologic Association Meeting, Kohler, WI. Paper delivered, "Brachytherapy for prostate cancer salvage after external beam radiation failure".
35. February 6, 2003, "Chemoprevention and the management of advanced prostate cancer", Invited speaker, Grand Rounds at St. Vincent Hospital, Green Bay, WI.
36. April 11, 2003, "Sural nerve grafting for prostate cancer", Invited speaker, News video for UW Comprehensive Cancer Center, Madison WI.
37. May 17, 2003, "Sural nerve grafting during radical prostatectomy" Invited speaker, Wisconsin Urologic Association Meeting, Milwaukee, WI.
38. August 4, 2003, "Induction of senescence for prostate cancer therapy", Invited speaker, Radiation Therapy Grand Rounds, UWCCC, Madison WI.
39. August 4, 2003, "Induction of senescence for prostate cancer therapy", Invited speaker, Prostate Group Meeting, UWCCC, Madison WI.
40. October 1, 2003. "New management strategies for prostate cancer", Invited speaker, St. Vincent's Hospital, Dubuque, IA.
41. October 3, 2003. "Sural Nerve grafting for prostate cancer". Invited speaker, UW Comprehensive Cancer Center Talk Symposium on Cancer Care, Monona Terrace Convention Center, Madison, WI.
42. October 17, 2003. "Radical Retropubic Prostatectomy". Invited speaker, 3rd Annual Uehling Lectureship, Monona Terrace, Madison, WI.
43. November 19, 2003. "Progression of hormone-independent cancer; Options for new therapies". Invited speaker, IUN talk in Milwaukee, WI.
44. February 16, 2004, "Are alterations in imprinting a susceptibility factor for prostate cancer?" Invited speaker, McArdle Seminar Series, University of Wisconsin, Madison WI.
45. April 2, 2004. "Senescence as therapy for prostate cancer", Invited speaker, UWCCC Prostate Group Meeting, Madison WI.
46. May 20, 2004. "Alterations in genomic imprinting as a susceptibility factor for prostate cancer with aging". Invited speaker, Workshop: Research at the Interface of Aging and Cancer, Waisman Center, Madison WI.
47. May 22, 2004, Panel on oncology and "High-dose zinc increases GU hospitalizations", Wisconsin Urologic Association Meeting, Madison, WI.
48. September 15, 2004, "New options for hormone-resistant prostate cancer", Invited speaker, IUN meeting, Appleton WI.
49. September 20, 2004. "Prostate Cancer", Invited speaker, Radiation Therapy residents and staff, Madison WI.

50. November 13, 2004, Panel on renal surgery, Third Annual Uehling lectureship, Madison, WI.
51. December 1, 2004. Invited speaker, Man to Man meeting, Madison, WI
52. December 15, 2004. "New options for hormone-resistant prostate cancer", Invited speaker, IUN meeting, Green Bay, WI.
53. February 15, 2005. "Diagnosis and treatment of prostate cancer in older men". Invited speaker, UW Geriatrics Department Grand Rounds, Madison WI.
54. May 7, 2005, "Management of high-risk prostate cancer", Invited speaker, Wisconsin Urologic Society Meeting, Lake Geneva, WI
55. May 11, 2005. "Screening for prostate cancer". Invited speaker, Outreach Appleton, WI.
56. August 27, 2005. "Urology Division Advances". Invited speaker, Wisconsin Surgical Club, Madison, WI.
57. January 6, 2006. "Are alterations in imprinting susceptibility factors for prostate cancer?" Invited speaker, UW O'Brien Urology Research Winter Forum, Madison WI.
58. April 22, 2006. "Advances in prostate cancer therapy". Invited speaker, Wisconsin Oncology Network meeting, Hilton Hotel, Madison, WI.
59. June 1, 2006. "Robotic prostatectomy", Invited speaker, Rockford IL
60. June 26, 2006. "Dr. Robot does the operation". [Front page article](#) in Wisconsin State Journal on my robotic prostatectomy operation. Madison, WI.
61. July 19, 2006. "Robotic prostatectomy", Invited speaker, Man to Man prostate cancer support group, Madison, WI.
62. September 6, 2006. "Induction of senescence as therapy for prostate cancer". Invited speaker, UW Comprehensive Cancer Center Grand Rounds, Madison WI.
63. September 22, 2006. "Robotic prostatectomy: The UW experience", Invited speaker, Uehling Lectures, Fluno Center, Madison, WI.
64. October 4, 2006. "Robotic Prostatectomy; The UW experience". Invited speaker, UW Surgery Grand Rounds, Madison WI.
65. March 12, 2007. "Robotic prostatectomy". Invited speaker, Attic Angels, Madison, WI.
66. September 14, 2007. "Alterations in Imprinting as Susceptibility Factors for Prostate Cancer", Invited speaker, Prostate Cancer Speaker series, UWCCC, Madison WI.
67. September 19, 2007. "Robotic prostatectomy: The UW experience". Invited speaker, Man to Man prostate cancer support group, Madison, WI.
68. May 2, 2007, "Management of High-risk Prostate Cancer", Visiting Professor, Medical College of Wisconsin, Dept. of Urology. Milwaukee, WI.
69. October 12, 2007. "Multimodality treatment of High Risk Prostate Cancer", Invited speaker, Uehling Lectures, Fluno Center, Madison, WI.
70. January 24, 2008. "LOI as a susceptibility factor for prostate cancer", Invited speaker, METC seminar, Madison WI.
71. October 17, 2008, "High risk prostate cancer" Invited speaker, Uehling Lectures, Fluno Center, Madison, WI.
72. January 7, 2009. "Prostate Cancer Update", Invited speaker, Finley Hospital Grand Rounds, Dubuque, IA
73. January 26, 2009. "Prostate cancer and aging", Invited speaker, Biology of Aging Speaker series, Madison WI.
74. May 18, 2009. "Prostate Cancer Screening and Treatment", Invited speaker, Divine Savior, Portage, WI
75. September 3, 2009. [Radio Interview](#) with Joy Cardeen. Wisconsin Public Radio. Madison, WI.
76. October 12, 2009. Interview for article in Milwaukee Journal Sentinel "Robotic prostate surgery not better at reducing side effects study finds". Milwaukee, WI.
77. March 3, 2010. Invited speaker, Presentation on cancer at Hamilton Middle School, Madison WI.

78. March 6, 2010. "Imprinting and prostate cancer", Invited speaker, Prostate Cancer Seminar, WIMR, Madison WI.
79. September 2, 2010. "Update on Prostate Cancer", Invited speaker, Dept. Urology Grand Rounds, Madison WI.
80. September 15, 2010. "Prostate Cancer Advances". Invited speaker, Man to Man Prostate Cancer Support Group, American Cancer Society, Madison WI
81. Dec 10, 2010. Interview for ABC TV (local) regarding prostate cancer screening. Madison, WI.
82. Feb 2, 2011. "Epigenetics and cancer susceptibility" Invited speaker, UW Genetics Colloquium, Madison, WI.
83. April 2, 2011. Moderator, Prostate cancer. Wisconsin Urologic Society, Milwaukee, WI
84. May 6, 2011. Interview for NBC (local). Screening for prostate cancer. Madison, WI.
85. November 15, 2011. Keynote speaker, "Prostate Cancer Progress", Night to Movember, Rockford Health, Rockford, IL.
86. November 18, 2011. Moderator, Testicular Cancer; Panel member, Prostate Cancer, Speaker 'Diagnosis of prostate cancer using a field defect', and Speaker 'Surgical management of high risk prostate cancer'. Uehling Lectures, Madison WI
87. June 13, 2012. "Prostate Cancer". Invited speaker, UW Mini Med School. Madison WI
88. Nov 9, 2012. Panelist and Discussant "Prostate Cancer". Uehling lectures, Madison Wisconsin
89. December 28, 2012. Invited Speaker. "Prostate Cancer: Treatment and Waiting" Man to Man, Madison WI
90. April 3, 2013. Invited Speaker. "Management of High Risk Prostate Cancer". Finley Hospital, Dubuque IA
91. January 18, 2014. Invited Speaker. "Changing landscape of prostate cancer management". Man to Man, Madison WI.
92. February 19, 2014. Invited Speaker. "Prostate Cancer" Community Urologic Education Series Madison WI.
93. November 12, 2014. Invited Speaker. "Field defect for prostate cancer diagnosis", First Look Forum, Investors Symposium. Monona Terrace, Madison WI
94. December 17, 2014. Invited Speaker. "Issues and Options in Prostate Cancer Diagnosis". Wednesday Nite @ the Lab, UW Biotechnology Center (Also shown on WPTV television)
95. June 2015. 'Triple Threat' Article detailing my treatment of golf pro and US Champion Andy North. By Susan Lampert Smith, UW alumni magazine.
96. October 2015. Jarrard DF. New Approaches for Management of Patients after Negative Prostate Biopsy. Uehling Lectures. Cutting Edge Treatment of Urologic Cancers. Madison, WI.
97. November 2015. Jarrard DF. Prostate Cancer and the Role of the Pathologist: The Surgeon's Perspective. Wisconsin Society of Pathology 2015 Annual Conference. Waukesha, WI.
98. April 16, 2016. Panelist and Discussant Prostate Cancer Wisconsin Urologic Society, Madison, WI.
99. July 2016. "Tech and Biotech: Wisconsin startup investment funding dips; D2P advances seven UW discoveries". Article regarding prostate biomarker discovery. By Judy Newman. *Wisconsin State Journal*.
100. October 2016. Speaker "Aging, Epigenetics and Cancer Discovery." Epigenetics Symposium. Pyle Center, Madison, WI
101. October 2016. Poster Decreased CTCF Expression Directs DNA Hyper methylation Events in Cancer Progression. Epigenetics Symposium 2016. Pyle Center, Madison, WI
102. November 25, 2016. TV interview with patient on prostate cancer twins. WMTV, Madison, WI.

103. September 22, 2017 Uehling-Wear Lecture Series. 'Advancing the Treatment of Genitourinary Cancers'. Series Organizer and speaker 'Impacting the treatment of hormone sensitive prostate cancer: A Novel Therapeutic Niche'. Madison, WI.
104. October 18, 2017. WARF Innovation awards 'Predicting Prostate Cancer in Tissue Biopsies'. Madison, WI.
105. March 16th 2019. Panel Discussion: Challenging Cases in Advanced Prostate Cancer. Wisconsin Urologic Society. Madison WI
106. November 16, 2022 'Whats new in prostate cancer detection and treatment' Gilda's Club Madison WI

National and International

1. September 1993, "Role of urokinase plasminogen activator and plasminogen activator inhibitor-1 in prostate cancer cell invasion", Invited speaker, American Urological Association North-Central Section Meeting, Milwaukee, WI.
2. September 29, 1996, "DNA methylation in prostate cancer", Invited Speaker, Eastern Cooperative Oncology Group Meeting, Miami, FL.
3. October 1997, Moderator, "Prostate Cancer Basic Science Research", Invited speaker, Annual Meeting of the North Central Section of the American Urological Association, Sedona, AZ.
4. May 29-June 4, 1998, "Loss of either p16/cdkn2 or RB is required for overcoming senescence in human prostate epithelial cells", Invited speaker, National Meeting of the American Urological Association, San Diego, CA.
5. November 12, 1998, "Methylation of the Androgen Receptor is associated with loss of AR expression in prostate cancer cell lines", Invited speaker, Society for Basic Urologic Research, Annual Meeting, Black Point Inn, ME.
6. December 2, 1998, "Alterations in the P16/ Retinoblastoma pathway is required for overcoming senescence in prostate epithelial cells", Invited Speaker American Association of Cancer Research special conference on New Approaches in the Prevention and Cure of Prostate Cancer, Palm Springs, CA.
7. December 2, 1998, "Alterations in the P16/ Retinoblastoma pathway is required for overcoming senescence in prostate epithelial cells", Invited Speaker American Association of Cancer Research special conference on New Approaches in the Prevention and Cure of Prostate Cancer, Palm Springs, CA.
8. October 26, 1999, "Senescence and overcoming senescence in prostate cancer progression", University of Chicago, Chicago, IL. Visiting Professor
9. April 3, 2000, Hidefumi Kinoshita, Yan Shi, Carol Sandefur, Lorraine F. Meisner, Chawnshang Chang, Aung Choon, Catherine R. Reznikoff, G. Steven Bova, Andreas Friedl, and David F. Jarrard "Methylation of the Androgen Receptor minimal promoter silences transcription in human prostate cancer", Invited speaker, American Association of Cancer Research Proceedings, Vol. 40, March 2000.
10. April 30, 2000, "Understanding Molecular Technology and its application to urology", Course taught at the National meeting of the American Urologic Association 95th Meeting, Atlanta, GA.
11. April 27, 2001, "Progression of hormone-independent cancer", Invited speaker, Aventis Oncology, San Francisco, CA.
12. May 5-9, 2001, Advances in Urology 2001, Sponsored by the Urologic Society of Argentina , "Molecular technology for the practicing urologist"; "Top ten urologic advances in molecular medicine"; "Applications of gene therapy to urology"; "The molecular genetics of prostate cancer". Invited talks, Buenos Aires, Argentina.
13. June 22, 2001, "Progression of hormone-independent cancer; Options for new therapies", Invited speaker, Aventis Oncology, New York, NY.

14. October 27, 2001, "Progression of hormone-independent cancer; Options for new therapies" Invited speaker, Aventis Oncology, Las Vegas, NV.
15. November 30, 2001, "Methylation of the Androgen Receptor Minimal Promoter Silences Transcription in Human Prostate Cancer", Invited speaker at the annual meeting of the Society of Basic Urologic Research, Tucson, AZ.
16. April 26, 2002, "Bypassing Senescence in Prostate Cancer Progression", Invited speaker at UW Prostate Cancer Symposium, Madison, WI.
17. July 26, 2002, "Progression of hormone-independent cancer; Options for new therapies" Invited speaker, Aventis Oncology, Cleveland, OH.
18. October 12-14, 2002, "Oxidative Stress in Prostate Cancer", Invited speaker and moderator at the 3rd annual University of Iowa Prostate Cancer meeting, Iowa City, Iowa.
19. January 12-14, 2003, "Reinduction of Senescence in Prostate Cancer", Invited speaker and guest at Louisiana State University Cancer Center, Shreveport, LA.
20. March 5, 2003, "Progression of hormone-independent cancer; Options for new therapies" Invited speaker, Aventis Oncology, Chicago, IL.
21. May 5, 2003, Invited talk on "Aging and Cancer: Are age-related alterations in genomic imprinting susceptibility factors for cancer?" Invited speaker, Pennington Scientific Symposium on Mechanisms and Retardation of Aging, Baton Rouge, LA.
22. September 14-17 2003. "Management of advanced prostate cancer" Course Director at North Central Section meeting of the American Urological Association, Vancouver, BC.
23. September 14-17 2003. "Induction of senescence in prostate cancer" and "Function of Indiana Pouch Urinary Diversion after Radiation Therapy", Invited speaker, North Central Section meeting of the AUA, Vancouver, BC.
24. December 2, 2003. "New options for the management of advanced prostate cancer", Invited speaker, IUN in Minneapolis, MN.
25. December 5-6, 2003. "Induction of senescence in prostate cancer" and "How to succeed as a physician-scientist". Invited talks given at the Society of Urologic Oncology annual meetings, Washington, DC.
26. June 18, 2004. "Update on prostate cancer", Invited speaker CME course given at Washington University, St Louis, MI.
27. June 17, 2004. "Senescence as therapy for prostate cancer". Invited research talk at Washington University Dept. of Urology, St. Louis, MI.
28. October 8, 2004. "New options in hormone-refractory prostate cancer", Course Director and speaker. North Central Section meeting of the AUA in Palm Beach, FL.
29. November 7, 2004. "Senescence as therapy for prostate cancer", Invited talk, Prouts Neck Prostate Cancer meeting, Black Point Inn, ME.
30. March 4-8, 2005. "A Loss of Insulin-like Growth Factor-2 Imprinting is modulated by CCCTC-Binding Down Regulation at Senescence in Human Epithelial Cells." Invited talk, American Association of Cancer Research Meeting on "Cell death, Senescence and Apoptosis". Keystone, CO.
31. July 11-15, 2005. Invited speaker. Gordon Conference on Hormone Action and Development & Cancer, "Are imprinting alterations age-related susceptibility factors for prostate cancer?", Mount Holyoke, MA.
32. September 7, 2005. Speaker and organizer for symposium on "Management of high-risk prostate cancer", Talk on "Adjuvant and neoadjuvant options for high-risk prostate cancer". North Central Section of the AUA, Chicago IL.
33. September 8, 2005. "Use of the appendix to lengthen the ureter during continent diversion", Oral presentation at North Central Section of the AUA, Chicago IL.
34. September 30, 2005. Invited talk at the Prostate Foundation Meeting (CAPCURE) on "Senescence as therapy for prostate cancer", Scottsdale, AZ.

35. November 28, 2005. Invited speaker, MD Anderson Cancer Center GU Oncology. "Senescence as therapy for prostate cancer", Houston, TX.
36. May 20, 2006. Moderator "Bone and the Microenvironment", Society of Urologic Oncology meeting, Atlanta, GA.
37. June 9, 2006. "Imprinting, Aging and Prostate Cancer: The Good, the Bad and the Ugly" Invited speaker, Brady Urologic, Johns Hopkins Hospital Dept. of Urology, Baltimore, MD.
38. November 17, 2006. "Are epigenetic alterations susceptibility factors for cancer with aging?", Invited speaker, Society for Basic Urologic Research, Annual Meeting, Phoenix, AZ
39. January 22, 2007. "Management of high-risk prostate cancer." Invited speaker, Ohio State University Urology, Columbus, OH.
40. March 12-13, 2007, Roswell Park Cancer Center, Dept. of Urology (Three lectures) Visiting Professor, Buffalo, NY.
41. September 5-8, 2007. IMPACT Department of Defense Prostate Cancer Meeting, Invited speaker "Senescence as therapy for prostate cancer", Atlanta, GA.
42. September 27-30, 2007. Basic Urological Research Congress, Invited Speaker "Loss of Imprinting as a Susceptibility Factor for Prostate Cancer", Dublin, Ireland
43. November 1-3, 2007. North Central Section of the AUA Annual Meeting, Podium Discussant Prostate Cancer. Hollywood, FL.
44. May 16-21, 2008. AUA Meeting, Moderator, Prostate Cancer Epidemiology, Orlando, FL.
45. September 25, 2008. North Central Section of the AUA Annual Meeting, Podium Discussant "Complex Cases in Prostate Cancer", Chicago, IL.
46. November 21-23, 2008. Invited Speaker "Age related Alterations in Genomic Imprinting and Prostate Disease Susceptibility". Society for Basic Urologic Research, Phoenix, AZ.
47. June 11, 2008. ABC National News "Ask the Doctor". Videotaped information on prostate biopsy.
48. April 26, 2009. AUA National Meeting, Moderator, Prostate Cancer Basic Research, Chicago, IL.
49. August 13-14, 2009 Aging and Comprehensive Cancer Center Meetings, Invited Speaker "Is LOI a susceptibility factor for prostate cancer development?" Denver, CO.
50. November 6-8, 2009. Invited Moderator. "Dialogues in Clinical and Translational Research", Society for Basic Urologic Research, New Orleans, LA
51. November 9-14, 2009. Poster Discussant "Prostate Cancer Research". 83rd Annual Meeting of the North Central Section of the AUA, Scottsdale, AZ.
52. October 27-28, 2010. "Therapy-Induced Senescence in Cancer" Invited speaker and seminar Purdue University Dept. of Medicinal Chemistry and Molecular Pharmacology, Lafayette, IN.
53. November 11-14, 2010. Meeting co-organizer and faculty. The Inflammation/Immunity Axis in Urologic Disease. Atlanta, GA
54. May 28-31, 2010. AUA National Meeting. Moderator, Prostate Cancer Basic Research, San Francisco, CA
55. Sept 29-31, 2010. Poster Discussant "Prostate Cancer Research" NCS Annual Meeting, Chicago IL.
56. March 1-2, 2011. "Loss of Imprinting as A Risk Factor for Prostate Cancer" and "Management of High Risk Prostate Cancer." University of Chicago, Division of Urology. Visiting Professor. Chicago, IL.
57. March 9-12, 2011. Invited Moderator: Genomics, IMPACT meeting, Orlando, FL
58. May 13-18 2011. Plenary Speaker, AUA national meeting "Prostate Cancer Basic Science" Washington, DC.
59. May 13-18 2011. Invited Moderator, AUA national meeting "Prostate Cancer Basic Science" Washington, DC.
60. July 16-17, 2011. Invited Speaker, "Aging and epigenetics as risk factors for prostate cancer". AUA summer research meeting. Baltimore, MD.

61. November 30, 2011 Invited Speaker and seminar “Do age-related changes in epigenetics underlie prostate cancer risk”, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.
62. Feb 2-4, 2012, Invited Speaker, “Prostate Cancer Recent Publications”, American Society of Clinical Oncology Genitourinary Cancer Symposium, San Francisco, CA
63. April 25-30, 2012 Invited attendee, American Association Genitourinary Surgeons, La Jolla, CA.
64. May 18-23, 2012 Plenary Talk, American Urologic Association National Meeting “Basic Science Highlights” Atlanta, GA.
65. May 18-23, 2012. Invited Moderator, Prostate Cancer Staging, American Urologic Association National Meeting, Atlanta, GA.
66. November 15-15, 2012, Invited Speaker, SBUR National Meeting “Alterations in IGF2 imprinting with aging. Miami, FL.
67. November 18-19, 2012, Invited Speaker and Seminar “Epigenetics and Aging: Biological and Clinical Implications”, University of Pittsburgh, Dept. of Urology, Pittsburgh, PA.
68. March 18-19, 2013, Invited Speaker, Clark Atlanta Prostate Cancer Symposium, “Age-Related Epigenetic Alterations Inducing Susceptibility.” Atlanta, GA.
69. May 4-9, 2013, Moderator, Prostate cancer staging, American Urologic Association National Meeting, San Diego, CA
70. July 8, 2013, Invited Speaker and seminar, Vanderbilt University Dept. of Urology, “Epigenetics as a susceptibility factor for prostate cancer?” Nashville, TN.
71. October 28, 2013. Invited Speaker and seminar, New York University School of Medicine, Dept. Pathology “Age-Related Epigenetic Alterations Induce Prostate Cancer Susceptibility”, New York, NY.
72. May 17, 2014. Meeting Organizer and Moderator. ‘The New Landscape of Therapy for Prostate Cancer’. Society of Urologic Oncology/Society for Basic Urologic Research Meeting morning meeting held in conjunction with the American Urologic Association National Meeting, Orlando, FL.
73. May 17, 2014. Meeting Organizer and Moderator. ‘High Risk Localized PC’, ‘Renal Cancer Heterogeneity: Clinical and Scientific Implications’ and ‘Multidisciplinary Therapy of Locally Advanced Prostate Cancer’. Society for Urologic Oncology afternoon meeting held in conjunction with the American Urologic Association National Meeting, Orlando, FL.
74. Sept 11, 2014. Moderator and Discussant. “Robotic Renal Surgery”. North Central Section Meeting of the AUA, Chicago IL
75. October 8-9, 2014. Invited speaker and seminar, “Age-related epigenetic alterations underlying prostate cancer: Biologic and Diagnostic Implications”. Grand Rounds, Wayne State Karmanos Comprehensive Cancer Center, Detroit MI.
76. October 10, 2014. Invited speaker and seminar, “Aging, epigenetics and prostate cancer susceptibility. JFCI Oncology Research Seminar, Henry Ford Medical Center, Detroit MI.
77. December 11, 2014 Invited speaker on the Joy Cardin Show, Wisconsin Public Radio, Madison, WI.
78. December 19, 2014. Invited speaker. “Histone modulators in CRPC”, Great Lakes SPORE Planning meeting, Detroit MI
79. April 3, 2015. “New Approaches to Diagnosing and Treating Prostate Cancer”, 60 min lecture televised on Wisconsin Public Television. Madison, WI.
80. May 16, 2015. Meeting Co-organizer. ‘Emerging Paradigms in Metastases’ Society for Urologic Oncology and Society for Basic Urologic Oncology joint morning meeting, New Orleans, LA.
81. May 16, 2015. Meeting Organizer and Moderator. Society for Urologic Oncology afternoon meeting held in conjunction with the American Urologic Association National Meeting, New Orleans, LA.

82. May 16, 2015. Invited Speaker. 'Prostate Cancer Biomarkers For Tailored Therapy: Value Added Or Only Cost 'Society for Urologic Oncology afternoon meeting held in conjunction with the American Urologic Association National Meeting, New Orleans, LA.
83. May 17, 2015. Invited speaker "Exploiting the Epigenetic Field Effect to Improve Prostate Cancer", Urologic Oncology Forum, American Urological Association Annual Meeting, New Orleans, LA
84. May 17, 2015. Moderator "Prostate Cancer: Basic Research III", American Urological Association Annual Meeting, New Orleans, LA
85. May 5, 2016 Invited Speaker, 'Gaining and Sustaining Grant Funding'. Society of University Urologists/ Society of Urology Chairpersons and Program Directors. American Urological Association Annual Meeting. San Diego, CA.
86. May 9, 2016. Invited Speaker, 'Evaluating Elevated PSA after Negative Biopsy'. Plenary session. American Urological Association Annual Meeting. San Diego, CA.
87. July 16, 2016 Invited Speaker, 'Epigenetics and Prostate Cancer: Susceptibility to Alteration with Aging and Opportunities for Biomarker Detection', Meeting 'Targeting epigenetics and genome regulation to improve health', Baltimore, MD.
88. Jan 8-9, 2017 Invited speaker and seminar, 'Employing Epigenetics to Improve Cancer Care' Medical College Wisconsin Dept. Urology and MCW Cancer Center, Milwaukee, WI.
89. May 10, 2017 Course Director and Speaker, Castration Resistant Prostate Cancer (CRPC) Live Forum for Residents and Fellows, 'Secondary Hormone Manipulation and Mechanisms of Progression to CRPC', Boston, MA.
90. June 16-17, 2017. Visiting Professor SUNY, 'Epigenetics and Prostate Cancer: Susceptibility to Alteration with Aging and Opportunities for Biomarker Detection' and 'Applying Innovation to Advanced Prostate Cancer Care'. Syracuse, NY.
91. September 23, 2017. Course Director and Speaker, AUA Castration Resistant Prostate Cancer (CRPC) Live Forum for Residents and Fellows, 'Secondary Hormone Manipulation and Mechanisms of Progression to CRPC' and "Manipulating the Androgen Axis", Cleveland, OH.
92. October 28, 2017. Course Director and Speaker, AUA Castration Resistant Prostate Cancer (CRPC) Live Forum for Residents and Fellows, 'Secondary Hormone Manipulation and Mechanisms of Progression to CRPC' Los Angeles, CA.
93. November 9, 2017. Gave the keynote AUA invited lecture to start the Society for Basic Urologic Research meeting: 'Epigenetics and Therapy of Urologic Cancers' Tampa Bay, FL.
94. January 25-26, 2018. AUAPlus course faculty 'Prostate Cancer Guidelines'; lecture and case discussions, Baltimore, MD.
95. February 8, 2018. Discussant and moderator Society for Academic Urology Program Directors and Coordinators Annual Meeting, 'The Poor Learner – What Departmental and Institutional Tools Exist?' Miami FL
96. May 18, 2018. Course Director and Speaker, AUA Castration Resistant Prostate Cancer (CRPC) Live Forum for Residents and Fellows, 'Manipulating the Androgen Axis: Androgen Biosynthesis Inhibitors and AR Signaling Agents' San Francisco, CA.
97. May 20, 2018. Moderator "Prostate Cancer: Basic Research II", American Urological Association Annual Meeting, San Francisco, CA
98. May 20, 2018. Invited Speaker, 'AUA CRPC Guidelines Update'. Plenary Prime Time session. American Urological Association Annual Meeting. San Francisco, CA.
99. May 21, 2018. Invited Speaker, Instructional Course Director "Role of Chemotherapy for Metastatic Castration Resistant Prostate Cancer" and "Manipulating the Androgen Axis: Androgen Biosynthesis Inhibitors and Androgen Receptor Signaling Agents", American Urological Association Annual Meeting. San Francisco, CA.
100. September 6, 2018. 'Evaluating Prostate Cancer Risk: Germline mutations and susceptibility loci '. Talk and panel discussion, North Central Section AUA, Chicago, IL.

101. September 7, 2018. Discussant and Moderator. Prostate Cancer Podium Presentations. North Central Section of the AUA, Chicago, IL.
102. September 12, 2018. Live webinar and podcast 'Androgen Axis Agents and Bone Targeted Therapies in Advanced Prostate Cancer: What's New'. Produced for the AUA Office of Education.
103. October 17, 2018. Live webinar and podcast 'Sequencing of Chemotherapy and Immunotherapy in Advanced Prostate Cancer'. Produced for the AUA Office of Education.
104. November 8, 2018. Invited Speaker 'Focal Therapy for Prostate Cancer: Does the Data Support the Hype?' and 'Management of Oligometastatic Prostate Cancer: Treating the Primary'. 18th Annual Multidisciplinary Genitourinary Oncology Course: Focus on Prostate Cancer. Cleveland Clinic, Cleveland Ohio.
105. February 18-22, 2019, Invited Speaker and Course Faculty 'Imaging in the Surgical Management of Renal Cancer' and 'Impact of Imaging on the Clinical Care of Patients with Prostate Cancer'. 14th Oncologic Imaging: A Multidisciplinary Approach - Faculty from the Nation's Leading Cancer Centers. Havana, Cuba.
106. May 2, 2019. Speaker and Course Director "Evolving Role of the Urologist in Metastatic and Castration Resistant Prostate Cancer: A Guidelines and Case-Based Discussion". Sponsored by AUA and SUO, Chicago IL.
107. May 3, 2019. Invited Speaker, 'Second Opinion Cases: Ask the Guidelines: Advanced Prostate Cancer'. Plenary Prime Time session. American Urological Association Annual Meeting. Chicago, IL.
108. May 4, 2019. Invited Speaker, Instructional Course "Castration Resistant Prostate Cancer (CRPC) Guidelines and Therapeutic Advances in Metastatic Prostate Cancer", American Urological Association Annual Meeting. Chicago IL.
109. September 4 2019, Invited Presentation 'Robotic Prostatectomy Tips and Tricks'. North Central Section of the American Urological Association Annual Meeting. Chicago, IL.
110. September 5 2019, Presidential Address. 'Why Have We Not Yet Cured Urological Cancer? North Central Section of the American Urological Association Annual Meeting. Chicago, IL
111. September 6 2019, Invited Moderator 'The Future of Urology'. North Central Section of the American Urological Association Annual Meeting. Chicago, IL.
112. October 2-3, 2019. Invited Speaker and Visiting Professor, Annual Chung Lee Lectureship "Exploiting Unique Prostate Cancer Phenotypes To Improve Detection and Treatment", Northwestern University Lurie Cancer Center, Chicago IL.
113. November 4, 2019 "Current treatments and opportunities in advanced prostate cancer". Orion Collaborative Research meeting, Helsinki Finland
114. December 3, 2019. Course Director and Speaker, 'Evolving Role of the Urologist in Metastatic and Castration Resistant Prostate Cancer: A Guidelines and Case-based Discussion'. In conjunction with the Society for Urologic Oncology meeting. Wash DC
115. October 18-11, 2020. Faculty and speaker, Early Career Investigator Workshop sponsored by the AUA Research Foundation.
116. October 20, 2020. Course director and speaker, "The changing landscape of advanced prostate cancer treatment". AUA/SUO virtual meeting.
117. July 25, 2021. Moderator and discussant 'Clinical Trial Design' in Methods in Clinical Urology Research (MCUR) Workshop. AUA Office of Research
118. September 9, 2021. Course Director and Speaker, 'The Evolving Landscape of Advanced Prostate Cancer: a Guidelines and Case-based Discussion'. AUA Meeting 2021.
119. February 17, 2022 Speaker, 'Symposium on ADT for Castration-Sensitive Prostate Cancer'. GU ASCO, San Francisco

120. April 8th, 2022. Invited Speaker “Synthetic Lethal Metabolic Targeting of Short-term Androgen-Deprived Prostate Cancer Cells “. American Association of GU Surgeons, Palm Desert, CA
121. May 8th 2022. Course Director and Speaker. The Evolving Landscape of Advanced Prostate Cancer Treatment: A Guidelines and Case-Based Discussion, New Orleans LA
122. May 9th 2022. Invited Speaker ‘Strategies for Engaging Faculty and Residents in Translational Research”. Society of Academic Urology Annual Meeting, New Orleans LA
123. May 10th 2022. Invited Speaker. ‘Epigenetic Alterations That Drive Prostate Cancer With Aging Generate Biomarker Opportunities’ SUO/SBUR Combined meeting, New Orleans LA
124. May 11th, 2022. Course Speaker “A Guidelines Approach To Advanced Prostate Cancer”. AUA National Meeting, New Orleans, LA
125. August 25th, 2022. Invited Speaker ‘The Evolution of Management for High-Risk Prostate Cancer’. AUA New York Section Annual Meeting, Edinburgh, Scotland
126. September 19, 2022. Invited Speaker “The Evolving Landscape of Advanced Prostate Cancer’, Podcast recording AUA series
127. November 17, 2022 Invited Speaker, ‘Exploiting unique prostate cancer phenotypes to improve therapeutic responses’, Sidney Kimmel Cancer Center, Philadelphia via WebEx
128. September 14, 2023. Michigan Prostate SPOR meeting. Guest speaker. “Exploiting ADT-induced epigenetic and metabolic susceptibilities to improve prostate cancer outcomes”. University of Michigan Rogner Cancer Center via WebEx.
129. September 26, 2023. Collaborative Clinical Trials in GU Cancer. Presentation and meeting at Asan Cancer Center, Seoul Korea.
130. October 12th, 2023 Panelist and speaker ‘Localized prostate cancer management role of MRI and management’, North Central Section AUA, Scottsdale AZ
131. October 27th, 2023 Panelist and speaker, ‘Treatment of the primary in low volume metastatic disease’, Prostate Cancer Foundation Annual Meeting, Carlsbad CA
132. January 8-9, Visiting Professor, ‘Exploiting ADT-induced epigenetic susceptibilities to improve prostate cancer outcomes’, and ‘ New developments in the management of advanced prostate cancer ’ UCLA Dept Urology and UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles CA